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“A blind man knows he cannot see, and is glad to be led; but he that is blind 
in his understanding, believes he sees best and scorns guidance”  
Samuel Butler (1835-1902) 
 
“A recipe for ignorance is to be satisfied with your opinions and content with 
your knowledge, but the greatest ignorance is to reject something you know 
nothing about” 
Elbert Hubbard (1856-1915) 
 
“Experience is what you get, when you don’t get what you want” 
Dan Stanford 
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Abstract 
It has been shown that early interventional treatment of patients with high risk acute 
coronary syndromes (ACS) has a favourable effect on mortality. It is also known that 
coronary plaque rupture and atherothrombosis creates a mileu of necrotic and 
thrombotic material, which is difficult to treat. Moreover, angiographic assessment 
of coronary artery disease is highly flawed; 2-dimensional luminal silhouettes are not 
ideal templates to guide very important interventions. Intravascular ultrasound 
(IVUS) is the gold standard imaging tool able to delineate vessel dimensions, plaque 
burden, length and now with virtual histology (VH) - plaque composition. Despite 
optimal medical care and urgent revascularisation, 12-20% of ACS patients will 
suffer a further major adverse cardiac event (MACE) at 30 months. 
Our aim was to evaluate the angiographic treatment of high risk ACS patients by 
performing IVUS-VH pre and post-intervention, with the operators blinded to the 
images. Our hypotheses for this work were as follows: 
1. Significant compositional and structural differences exist between culprit, 
non-culprit and stable plaques when analysed by Virtual Histology. 
2. The histologically most unstable plaque does not occur at the site of 
maximum angiographic stenosis (in culprit lesions). 
3. Angiographically guided stent length selection and positioning is flawed, 
leaving unstable plaque behind in the reference segments. 
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Following recruitment, 135 lesions split into: 70 ACS culprit; 20 ACS non-culprit 
and 35 Stable lesions underwent analysis for inter-observer and intra-observer 
variability. We were able to show good standard markers of correlation but a large 
repeatability co-efficent, for some outputs from the analysis. This has raised 
questions with regard to the ability of the technique to detect differences between 
plaque types. 
In relation to our main hypothesis, we have been able to show structural and 
compositional volume differences between “active” ACS plaques (n=70) and 
“stable” angina plaques (n=35). We have used the most important of these to 
generate a plaque risk score based upon ROC statistics and logistic regression. The 
most important discriminators were: Remodelling index at the minimum lumen area; 
Plaque Burden; Presence of VH-TCFA; minimum lumen area (MLA) <4mm2 and 
necrotic core to dense calcium ratio (NC/DC). The subsequent risk model was 
tested on an independent, blinded cohort of plaques from the Thoraxcentre, 
Rotterdam (n=50). This confirmed good discriminatory power for the equation 
(AUC – 0.71). Within this hypothesis we also explored the differences in individual 
areas of plaque. At two separate sites (MLA and MAX NC) in each lesion type (ACS 
and stable) n=210, we showed that the MAX NC site lies proximal to the MLA in 
most cases and contains more positively remodelled plaque disease with less 
calcification. This is important as positively remodeled plaque disease is often not 
visible on a plain coronary angiogram when treating ACS lesions. 
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Finally, as a follow on from thie previous chapter, we examined the treatment of 
ACS lesions by blinded IVUS examination. The operator completed their stent 
procedure with only angiographic guidance. We were able to show in 56 ACS lesions 
that systematic errors of judgement occur related to sizing of the vessel, the choice 
of stent sizes and the subsequent stent deployment. 36%, 40% and 65.5% of stents 
met three separate standard criteria for good stent deployment. Moreover, between 
5-40% of stents had some form of significant abnormality. With regard to the sizing 
of stents to the vessel, the mean reference vessel size was 10.58mm2 (±2.51) yet the 
minimum stent area achieved was only 6.79mm2 (±2.43). If the stent that was 
chosen had been symmetrically deployed to its nominal size (e.g 2.5; 3.0; 3.5) then 
the stent area achievable should have been 8.87mm2 (±2.68). This has allowed us to 
calculate for the first time an estimated “under deployment area”. This was 2.08mm2 
(±1.87).  
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In conclusion we have shown that IVUS-VH can help discriminate active ACS 
plaques from stable angina plaques and can formulate a plaque risk score to aid 
plaque identification in the future. We have characterized the longitudinal anatomy 
of the ACS plaque and how this impacts on the percutaneous treatment of these 
lesions. We have also confirmed that angiography alone, as a guide for the treatment 
of ACS lesions, leads to systematic sizing and placement errors. These could have an 
affect on long term outcomes, in both the stent and the stented vessel. Our findings 
have added to the literature on this subject and provided some hypothesis generating 
conclusions that could be taken forward to improve the recognition and appropriate 
treatment of high risk plaques in the future. 
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IVUS in Interventional cardiology 
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1.1.1 Introduction 
Intravascular ultrasound (IVUS) is the generic name for any ultrasound technology 
used in-vivo within blood vessels. IVUS has evolved into an adjunct to interventional 
cardiology and it is this role that forms the basis for investigation in this thesis. This 
introductory information describes the technology from its inception and places it in 
its current clinical context, especially in relation to contemporary interventional 
cardiology. Initially, background descriptions are provided of coronary artery disease 
and the development of invasive cardiology. This will allow a more adequate 
understanding of the basis for the main research questions. Chapter II will then deal 
with an overview of the latest technology, as IVUS continues to evolve. 
1.1.2  Coronary artery disease 
The coronary arteries are the blood vessels that carry oxygenated blood to the 
myocardium (the muscle of the heart) and they arise from the aorta just above the 
aortic valve. There are usually two, the left and the right. The left divides into two 
branches, the left anterior descending (LAD) and the circumflex (LCx), and these 
further subdivide into a series of branches that supply predominantly the left 
ventricle. The initial part of the left coronary artery before it divides is known as the 
left main stem (LM). The right coronary artery (RCA) supplies the right ventricle and 
a variable amount of the inferior surface of the left ventricle. Coronary artery disease 
is the development of narrowings (stenoses) in the walls of the coronary arteries 
caused by deposits of atheroma (a collection of lipid, collagen and inflammatory cells 
in the artery wall) that eventually leads to partial or complete obstruction of normal 
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blood flow and the development of myocardial ischaemia. Atheroma of the coronary 
arteries presents in a variety of ways, including stable or unstable angina, acute 
myocardial infarction (AMI) or sudden death. These events can be described by the 
acronym MACE (major adverse cardiac event) and are: death, ST elevation 
myocardial infarction (STEMI), non-ST elevation myocardial infarction (NSTEMI) 
and revascularisation. The pain of myocardial ischaemia is characterised by a heavy, 
pressing chest pain that may be mistaken for indigestion, but also typically radiates to 
the jaw or left arm. The major difference between unstable angina and MI is the 
presence of myocardial cell death or necrosis with infarction, usually defined by 
blood analysis for the myocyte protein troponin. In recent years it has become 
increasingly clear that these are different expressions of the same underlying 
pathophysiological process, namely plaque rupture or erosion and partial or total 
coronary occlusion, which may be transient or permanent [Falk et al 1983, Virmani 
et al 2000]. Atherosclerosis is a lipoprotein-driven disease that leads to plaque 
formation at specific sites of the arterial tree through intimal inflammation, necrosis, 
fibrosis, and calcification. After decades of indolent progression, such plaques may 
suddenly cause life-threatening coronary thrombosis presenting as an acute coronary 
syndrome. Most often, the culprit morphology is plaque rupture with exposure of 
highly thrombogenic, red cell–rich necrotic core material. The permissive structural 
requirement for this to occur is an extremely thin fibrous cap, and thus, ruptures 
occur mainly among lesions defined as thin-cap fibroatheromas. Also common are 
thrombi forming on lesions without rupture (plaque erosion), most often on 
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pathological intimal thickening or fibroatheromas. However, the mechanisms 
involved in plaque erosion remain largely unknown, although coronary spasm is 
suspected. The calcified nodule has been suggested as a rare cause of coronary 
thrombosis in the highly calcified arteries of older individuals. 
However, It is clear from autopsy studies that these manifestations of coronary 
artery disease form part of a spectrum, with substantial overlap. [Burke et al 1997; 
Kolodgie et al 2004] 
1.1.3  Epidemiology  
Heart and circulatory disease is the UK's biggest killer.  In 2007, cardiovascular 
disease (CVD) caused 34% of deaths in the UK and killed just over 193,000 people. 
Coronary heart disease, the main form of CVD, causes over 90,000 deaths a year in 
the UK: approximately one in five deaths in men and one in six deaths in women. 
Although death rates for CHD have been falling rapidly in the UK since the late 
1970s, they are still amongst the highest in Western Europe [Allender et al BHF 
statistics 2008].  Data from the 2006 Health Survey for England suggest the 
prevalence of CHD in England was 6.5% in men and 4.0% in women. Prevalence 
rates increase with age, with more than 1 in 3 men and around 1 in 4 women aged 75 
and over living with CHD. Although recently deaths from heart and circulatory 
disease are falling, it remains the biggest killer in the UK. 
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 Almost 1 in 5 men and 1 in 8 women die from heart disease. 
 Heart Disease is responsible for 82,000 deaths in the UK each year, an 
average of 224 people each day. 
 More than 26,000 people under the age of 75 in the UK died from Heart 
Disease in 2009 
 There are nearly 2.7 million people living with heart disease in the UK. 
 There are more than 1.6 million men and more than a million women with 
heart disease in the UK. 
 Death rates from heart disease are highest in Scotland and northern England 
and lowest in southern England. 
 The UK spends 3.2 billion each year on healthcare costs for heart disease. 
 Most deaths from heart disease are caused by a heart attack. 
 There are around 124,000 heart attacks in the UK each year. 
 Around 62,000 men and 39,000 women in England suffer a heart attack each 
year. 
 In England, around 11% of men and 15% of women who were admitted to 
hospital with a heart attack die within 30 days. 
  
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 The chances of dying from a heart attack increases with age and is higher in 
women than men. 
 We estimate there are around 1,000,000 men and nearly 500,000 
women living in the UK who have had a heart attack. More than 900,000 of 
these are under the age of 75. 
 In Scotland, the number of heart attacks each year has decreased by around 
25 per cent between 2000 and 2009 in both men and women, but is between 
20 per cent and 35 per cent higher than England's incidence level. 
 Every six minutes someone dies of a heart attack in the UK. 
 One in three people who have a heart attack die before reaching hospital. 
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1.1.4 Pathophysiology 
The fundamental processes underlying coronary atheroma are endothelial 
dysfunction, lipid accumulation and smooth muscle cell proliferation [Yusuf S et al 
2001, Virmani et al 2006]. As the atheromatous plaque enlarges, the vessel grows to 
accommodate this by remodelling positively. This process is an attempt to prevent 
luminal narrowing and blood flow disturbance. This growth, highlighted first by 
Glagov et al in 1987, (figure 1.1) can continue until the vessel has grown by 40% of its 
original size. Further plaque enlargement, at this stage, results in luminal 
encroachment and eventually blood flow is restricted. A stenosis of more than 50% 
can be of haemodynamic significance, with compromise to coronary flow with 
effort. As myocardial work increases, for example, with exercise, myocardial oxygen 
demand increases. This is normally accommodated by an increase in coronary blood 
flow. However, as demand exceeds supply, the myocardium becomes ischaemic and 
angina is the symptomatic expression of this. Nevertheless, not all ischaemia causes 
angina. The threshold at which ischaemia causes pain varies between patients and 
most have episodes of silent ischaemia that are unaccompanied by pain. In some 
patients all ischaemic episodes may be silent. The acute coronary syndromes 
(NSTEMI and STEMI) occur when coronary plaque erodes or ruptures. The lining 
of the coronary artery overlying the plaque (the endothelium) tears and exposes the 
plaque core to the flowing blood. The plaque core contains a variety of highly 
thrombogenic substances and through the processes of platelet aggregation and 
fibrin formation, the lumen becomes acutely narrowed or occluded.  
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This causes a sudden severe reduction in blood flow with resultant myocardial 
ischaemia at rest, presenting as unstable angina. If the vessel becomes partially or 
completely occluded or distal embolisation of plaque occurs, and this is sustained, 
then myocardial tissue may die. This is MI (NSTEMI or STEMI). The precise 
process of atherogenesis is multiple and complex but is being unlocked slowly be 
scientific and molecular advances. However, a variety of factors are associated with 
an increased risk of developing coronary artery disease. [Dawber et al 1959, Lloyd-Jones 
et al 2010] The best characterised of these are smoking, diabetes mellitus, 
hypertension, hypercholesterolaemia and a family history of premature coronary 
artery disease. Patients with one or more of these abnormalities are more likely to 
develop angina or have a myocardial infarction. Based on the Framingham data 
[Wilson et al 1998, D’Agostino et al 2000], there are now risk functions by which the 
possibility of death or non-fatal MI can be estimated over a 10-year period for 
patients with various constellations of risk factors. [Wilson et al 1998] 
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Figure 1.1: Graphical representation of the Glagov phenomenon. (Adapted from 
Volcano Corporation Slide set (permission granted)) 
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1.2 Interventional cardiology 
1.2.1 Initial developments 
Mason Sones first carried out selective coronary angiography in October 1958. Some 
20 years later, in September 1977, Andreas Gruentzig carried out the first 
percutaneous transluminal coronary angioplasty (PTCA) in Zurich, Switzerland. 
Subsequently, there has been an exponential growth, both in the range of techniques 
and their indications. The number of percutaneous coronary interventions (PCI) 
carried out annually in the UK is now 94,000 nearly five times more than a decade 
ago.  This number is currently increasing at a rate of 5% per year. [Ludlam et al 2009]. 
The concept of PCI is fundamentally simple. The coronary artery is selectively 
engaged with a guide catheter (a one metre length of tubing with a diameter slightly 
over 2 mm), which has been introduced into the arterial circulation via either the 
femoral or radial artery. A guide wire (0.014 inches or 0.36 mm in diameter) is 
passed up the catheter to the coronary artery and steered into the artery and across 
the stenosis. An appropriately sized balloon catheter is then passed over the wire so 
that it follows into the narrowing. The balloon is inflated to somewhere between 4 
and 16 atmospheres. The aim is for the stenosis to have been reduced following 
dilatation and to remove haemodynamic significance.  
As originally conceived by Gruentzig [Gruentzig et al 1987], this was applied to 
patients with limiting chronic stable angina and discrete stenoses in a single coronary 
artery (usually the LAD). In subsequent years, the complexity and number of lesions 
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and vessels subjected to angioplasty have expanded. Interventions are now 
undertaken in saphenous vein grafts, multivessel disease and chronic total occlusions 
(CTOs). They are also undertaken urgently in patients with acute STEMI and 
NSTEMI. Even some unprotected left main stem disease with concomitant three 
vessel disease is able to be treated safely now by the interventional 
cardiologist.[Serruys et al 2009] This diversification has only been possible because of 
the dramatic improvements and research into the technology of interventional 
cardiology, with improved guide catheters and balloons, steerable guidewires and 
additional devices, such as bare metal and drug eluting stents, rotational 
atherectomy, thrombus aspiration and better imaging with digital systems and IVUS.  
1.2.2 Problems with “plain old” balloon angioplasty (POBA) 
As experience grew, it became apparent that there were problems such as acute 
recoil and restenosis associated with POBA. IVUS development helped address 
these issues and provide solutions [Mintz et al 1996, Stone et al 1997]. It became 
apparent that lesion characteristics influence the outcome of POBA [Kornowski et al 
1997, Gil R et al 1996, Baptista et al 1996]. For example, Short discrete concentric 
lesions are more likely to respond successfully to angioplasty than long, eccentric 
calcified ones [Tenaglia et al 1992, Jain et al 1994]. Lesion dissection, recoil and acute 
occlusion was common. A variety of devices were therefore developed to deal with 
some of these problems. This often involved some form of ‘debulking’ in which the 
burden of atheroma in the vessel is reduced prior to angioplasty.The choice of 
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device might have been guided, back then, by information acquired using IVUS 
[Weissman et al 1995, Mintz et al 1994]. 
1.2.3 Stent Technology 
The introduction of intra-coronary stents has revolutionised the practice of 
interventional cardiology. Stents are endoprosthetic scaffolding devices, usually 
metallic and based on a slotted tube or a coil design. They are deployed on a balloon 
and inflation of the balloon expands the stent against the wall of the coronary artery. 
Stents seal dissections, provide radial strength to combat recoil and create a rounder, 
smoother channel within the vessel, enlarging the lumen. In the early days, stents 
had limited application because they were unwieldy and not easily deployed into 
tortuous vessels or complex lesions. However, there has been exponential 
development in stent design and they now come in a range of diameters and lengths, 
pre-mounted on dedicated balloons. Initially, stents were used to treat arteries that 
had become acutely occluded during angioplasty (bail-out stenting) [Sigwart et al 1987 
and 1988, de Feyter et al 1991]. Subsequently, in 1994, they were shown to reduce 
restenosis rates in certain lesion subsets in both the BENESTENT and STRESS 
trials [Serruys et al 1994, Fischman et al 1994] Stenting practice was again modified 
when IVUS was used to evaluate the success of stent deployment [Goldberg et al 1994, 
Hall et al 1994]. IVUS demonstrated that many stents were not fully deployed at 
conventional dilation pressures (6–8 atmospheres). A subsequent high-pressure 
deployment strategy, with bigger post-dilatation balloons, achieved better results, 
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reducing stent thrombosis and in-stent restenosis. [Colombo et al 1995, Werner et al 
1997] and this has now become standard practice. 
 
 
Figure 1.2: Example of an inflated coronary stent on the delivery balloon 
(adapted from Wikipedia) 
 
 
1.2.4 Problems with Stents 
While Bare Metal Stents (BMS) reduced the re-stenosis rate in appropriate lesion 
subsets, they did not abolish it [Hoffman et al 1996 and 1997, Kastrati et al 1995]. The 
subsequent reduction in MLD due to new tissue growth (neo-intimal hyperplasia) 
within the stent created the phenomenon of “late loss” in around one third of 
patients at six months. Unfortunately, when it does occur, in-stent re-stenosis is 
more difficult to treat than re-stenosis after angioplasty alone.  
This led to the development of the Drug Eluting Stents (DES), which revolutionised 
the outcome of PCI by blocking the proliferation of re-stenosis and reducing rates 
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down to single figures. These improved late angiographic outcomes and reduction in 
future intervention for re-stenosis were shown in the first randomised trials utilising 
the Cypher stent [RAVEL, SIRIUS, C-SIRIUS and E-SIRIUS 2002-2003]. As time 
passed and utilisation of DES rose, it was clear that in solving the re-stenosis 
problem, a new problem had emerged, - late stent thrombosis [Pfisterer et al 2006, 
Lagerqvist et al 2007] As DES prevents neo-intimal proliferation and remains seen as 
a “foreign body” for sometime in the patient, thrombotic activation around this site 
is common. This especially seems to happen in relation to other patient factors such 
as anti-platelet discontinuation or resistance and inter-current illness or surgery.  
In the last few years, IVUS has been utilised again and again to solve the problems 
generated by coronary intervention. The precise understanding of intra-vascular 
pathology both pre and post-stenting, will allow us to take the next step in 
identifying plaques and stents with vulnerable features, that are likely to create future 
problems.  
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Figure 1.3 Schematic of an IVUS catheter in a blood vessel 
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1.3 IVUS 
 
1.3.1 Background 
Contrast angiography has been the gold standard in the assessment of coronary 
artery disease for over four decades. However, angiography only provides a 2-D 
sillouhette of the coronary lumen and gives no insight into the degree of atheroma in 
the vessel wall. As discussed above, pathological studies reveal that before 
atherosclerosis encroaches on the lumen, there is compensatory enlargement of the 
coronary artery, the Glagov phenomenon. [Glagov et al 1987] Lumen area is not 
compromised until plaque area exceeds 40% of the total vessel cross-sectional area. 
IVUS has enabled this phenomenon to be studied in-vivo and confirmed its existence 
[Gerber et al 1993, Ge et al 1994 ,  Hermiller et al, 1993 Mintz et al 1996]. IVUS also 
highlights that, in some cases, vessel size could reduce in the presence of atheroma 
(negative remodelling or reverse Glagov) [Pasterkamp et al 1995]. IVUS has been the 
most useful tool (over the years) to improve and facilitate knowledge of the intra-
vascular anatomy, that surrounds the interventional treatment of coronary disease. 
These ongoing insights have led to IVUS being seen as a tool that can assist the 
interventionalist and push forward the improvement of intra-vascular procedures. 
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Figure 1.4: Angiographically patent vessels containing variation in IVUS 
plaque burden at points A/B/C/D, despite the normal angiographic calibre 
(Adapted from Volcano Corporation, permission granted) 
 
 
IVUS uses the principles of echocardiography by generating very high frequency 
sound waves (ultrasound) from electrically stimulated piezo-electric crystals in the 
transducer. These ultrasound waves bounce off the various types of tissue structures 
in the body and the amplitude of the returned signal is used to generate the image.  
Intravascular Ultrasound transducers have been miniaturized to less than four 
hundredths of an inch and placed on the tip of a catheter. This catheter can be 
placed into the coronary arteries over the same guidewire that is used to position the 
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angioplasty balloons or stents. It becomes, in effect, a tiny camera that gives us a 
cross-sectional view of the artery, a view that shows distinct circular layers, using 
shades of grey, the major ones being: 
Figure 1.5: A typical cross-sectional frame of IVUS (courtesy of Volcano) 
 
 
 
1. The adventitia or outer muscular covering of the artery 
2. The media or wall of the artery  
3. The intima or layer of endothelial and other cells that make direct contact 
with the blood inside the artery. In normal arteries this layer is very thin. 
However,  in diseased arteries (as shown) the intima is thickened by 
atheromatous plaque in an eccentric or asymmetrical manner.  
4.  The lumen, the actual channel of the artery through which the blood flows. 
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Figure 1.6: A more complex cross-sectional frame of IVUS.                             
(Source Medscape) 
 
 
 
1.3.2 Adjunct to stent implantation 
Theoretically, IVUS guidance can facilitate optimal long-term results from stenting 
in three ways: first, by ensuring that significant residual stenosis or dissection at the 
stent margins is dealt with; second, by ensuring that plaque calcification that might 
limit stent expansion is identified and removed, for example, by Rotablation; third, 
by ensuring that an optimal lumen gain has been achieved in the stented segment. 
Criteria have been developed that define the achievement of optimal stenting (The 
‘MUSIC’ criteria) [De Jaegere et al 1996 and 1998]. These are based on a comparison of 
the lumen within the stent with the lumen of proximal stent and distal stent 
reference segments. This is together with the presence of complete stent apposition 
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to the vessel wall and a symmetrical stent expansion index related to the ratio of 
minimal to maximal stent lumen diameter. The lessons of bigger post-dilatation 
balloons and high pressure inflations that have been gleaned from the many early 
IVUS studies such as: AVID; OPTICUS; CLOUT; RESIST; WEST-2; STRUT; 
STARS and CRUISE are now used in most centres to improve angiographic results. 
It is known from the POST registry [Uren et al 2002] that in cases of stent 
thrombosis there was retrospective evidence of an abnormal IVUS in 94% of the 
cases.  
1.3.3 Grey-scale IVUS guidance in the bare metal stent era . 
In the studies mentioned above, the use of intravascular ultrasound as an adjunct to 
percutaneous coronary intervention, using bare metal stents, produced the following 
general findings: 
1.  IVUS guidance resulted in a significantly larger mean post-intervention 
angiographic minimal lumen diameter compared to angiographic guidance 
alone. 
2.  IVUS guidance resulted in a reduction in the odds of target lesion 
revascularization (repeat percutaneous coronary intervention or coronary 
bypass graft) compared to angiographic guidance alone. The reduction was 
statistically significant at a follow-up period of 6 months to 2 years. 
3.  Total revascularization rate (either target lesion or target vessel 
revascularization) was significantly lower for IVUS-guided patients at 18 
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months to 2.5 years after intervention. The main benefits were seen in long 
lesions and smaller calibre vessels. 
4.  There were no statistically significant differences in the odds of death or 
myocardial infarction between IVUS-guidance and angiographic guidance 
alone at up to 2.5 years of follow-up. 
5.  The odds of having a major cardiac event (defined as death, myocardial 
infarction, and target lesion or target vessel revascularization) were 
significantly lower for patients with IVUS guidance compared to 
angiographic guidance alone during follow-up periods of up to 2.5 years.  
However, in these studies, the reduction in the odds of combined events, reflects 
mainly the reduction in revascularization rates. 
1.3.4. IVUS guidance of drug-eluting stent placement. 
The MAIN-COMPARE registry [Park et al 2010] shows that IVUS guidance of left-
main procedures using DES can have a profound impact on mortality. The risk of 3 
year mortality was 60% lower in the IVUS arm versus angiography (figure 1.7).  
Other studies such as Roy et al   2007, have also proposed that IVUS guidance during 
PCI may reduce the rate of DES thrombosis. The JSAP trial (Nigishaki et al 2008) 
showed that PCI guided by IVUS in stable angina provided better outcomes than 
medical therapy alone, which is different from all previous stable angina trials 
comparing medical therapy with PCI.  
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One-year data from the Washington Hospital Center (WHC) IVUS vs. No IVUS 
DES Study show that patients in the IVUS group had: 
 65% lower stent thrombosis 
 29% lower TLR  
 The study concluded that using IVUS during DES implantation has the 
potential to influence treatment strategy and affect both DES thrombosis and 
the need for repeat procedures. 
  
Figure 1.7 – Results of the MAIN-COMPARE IVUS in LMS study 
(adapted from Volcano Corp slideset) 
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Moreover, as reported by Costantini et al 2008, patients in the IVUS group had the 
following lower rates compared to those in the non-IVUS group: 
 62% lower Stent Thrombosis 
 29% lower Target Vessel Failure (TVF) 
Figure 1.8 – Results from Costantini et al (adapted from Volcano Corp 
slideset) 
 
Compared with angiography, IVUS has the unique ability to assess suboptimal 
results of stenting, which may be associated with the occurrence of stent thrombosis. 
Previously, IVUS evaluations of stent under-expansion, incomplete lesion coverage, 
small stent areas, large residual plaque, and poor apposition have been found to 
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predict stent thrombosis after DES placement [Okabe et al 2007, Sonoda et al 2004. 
Fuji et al 2005, Costa et al 2005]. 
1.3.5 Recent updates to the IVUS evidence   
Figure 1.9.1  – Final results of ADAPT DES 
 
Recently, the largest ever study conducted with IVUS guidance [Witzenbichler et al 
2014] has reported its findings. In the ADAPT-DES (Assessment 
of Dual AntiPlatelet Therapy with Drug-Eluting Stents) trial, over 8500 real-world 
patients (no clinical or anatomic exclusions) underwent PCI and received at least one 
drug-eluting stent. IVUS guidance was prospectively examined with 5200 cases not 
using IVUS and 3300 cases using IVUS. The results shed new light in favor of IVUS 
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use: as IVUS guidance improved clinical outcomes both acute (<30 Days) and at 1 
year with both: 
            • 33% reduction in MI. 
            • 50% reduction in subacute and late stent thrombosis. 
These results are despite 40% more IVUS patients initially presenting with 
STEMI. IVUS guidance changed the procedure 75% of the time. Longer, 
more appropriately sized stents, bigger balloons (pre/post dilatation) were used at 
higher pressures with no negative impact on outcomes. 
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Table  1.1 - Basic comparative results from ADAPT-DES  
  
IVUS group 
(n=3343) 
Non IVUS group 
(n=5233) 
P 
value 
Any ST within 1 year 0.52% 1.04% 0.01 
- Acute (< 24 hours) 0.06% 0.04% 0.66 
- Subacute (1-30 days) 0.27% 0.56% 0.05 
- Late (31 days – 1 year) 0.25% 0.48% 0.1 
All-cause death/MI within 1 
year 
3.96% 5.35% 0.004 
Cardiac death within 1 year 0.84% 1.17% 0.1384 
Peri-procedural MI 1.26% 1.53% 0.3 
Non peri-procedural MI within 
1 year 
1.23% 2.17% 0.002 
 
Overall, In ADAPT-DES, operators who used IVUS pre and post-procedure were 
found to achieve greater maximal lumen areas for proximal reference lumen area (8.9 
vs. 7.6 mm2), in-stent lumen area (6.3 vs. 5.8 mm2) and distal reference lumen areas 
(6.5 vs. 6.1mm2, P<.0001 for all measures). Greater maximum lumen area is 
identified as a key procedural factor to reduce the risk for stent thrombosis with 
DES. 
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 In addition, a recent large meta-analysis by Zhang et al 2014, has shown in 19,619 
patients from both randomised and observational studies that a mortality benefit 
exists for IVUS guided stent implantation. It seems that by improving acute stent 
results we can improve event-free survival compared to angiographic guidance alone 
 
Figure 1.9.2  Forrest plots from Zhang et al 2014 – Permission requested 
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1.3.6 IVUS based tissue characterisation 
The development of plaque tissue characterisation with IVUS in 1990s [Moore et al 
1998, Nair et al 2002] heralded a new way of thinking about the percutaneous 
treatment of atherosclerosis, with more thought being put into the vulnerability of 
plaque. The study of plaque composition in different groups of patients appears to 
be the only current way to improve our knowledge about the natural history of this 
disease. In order to solve the problem of plaque progression, plaque rupture and re-
stenosis, we must observe plaque with these new techniques to hopefully develop a 
strategy to improve plaque recognition and subsequent treatment strategies. The 
natural progression from grey-scale plaque characterisation was realised with the 
introduction of crude grey scale correlations and eventually a computer based 
algorithm generating a colour coded map, developed from the backscattered 
ultrasound signals taken from the plaque. This leap forward was made with the help 
of expert pathologists and is now called Virtual Histology.  
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Chapter II - Introduction 
Virtual Histology and Acute Coronary Syndromes 
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2.1 Introduction 
Acute coronary syndromes (ACS) frequently cause considerable morbidity and 
mortality with a high risk of further events within the following year despite the use 
of optimal medical therapy and percutaneous coronary intervention (PCI) [Eagle et al 
2004]. Numerous studies have described the concept of acute, partial or complete, 
thrombotic occlusion of the coronary artery which occurs at the site of a friable 
atherosclerotic plaque with a lipid-rich necrotic core and a ruptured overlying thin 
fibrous cap (‘culprit lesion’) [Kolodgie et al 2004, Surmely et al 2006]. Moreover, this 
process initially appeared independent of the severity of the underlying stenosis 
[Falk et al 2005]. Most of our initial knowledge about the morphological 
characteristics of culprit lesions has been obtained from necropsy studies of lesions 
at the extreme end of the ACS spectrum [Uemura et al 2006]. The development of 
Intravascular Ultrasound (IVUS) with Virtual HistologyTM (VH), using spectral 
analysis of the radiofrequency ultrasound backscatter signals to identify the 
components of atherosclerotic plaque, has allowed some in-vivo delineation of the 
relative contributions of necrotic core and fibrous atheroma in unstable lesions 
[Nasu et al 2006, Surmely et al 2007, Fujii et al 2005]. This evidence suggests that there 
may be variations in the morphology of plaques which rupture and promote 
thrombosis in ACS, rather than the traditionally accepted view that a common 
pathological mechanism is at play. This imaging modality therefore provides great 
potential for in vivo information about the culprit lesion {Konig et al 2007].  
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The spectrum of coronary heart disease is heterogenous. Most acute events arise 
from lesions which were originally non-flow limiting [Virmani et al 2000]. Precise 
lesion characteristics or lesion staging could influence interventional and medical 
treatment but currently this has not been evaluated. Clinically, ACS presentations 
vary from unstable angina to non-ST/ST elevation myocardial infarction (NSTEMI, 
STEMI). Considerable variation exists in the degree of myocardial injury, assessed by 
troponin release and the extent of myocardial ischaemia, as demonstrated by patient 
symptoms and electrocardiographic changes. Moreover, the response of patients to 
conventional pharmacological therapy with respect to the resolution of myocardial 
ischaemia is variable, ranging from a single episode of chest pain to prolonged, 
intractable symptoms. This variation is multifactorial and, as well as clinical factors, 
includes the extent of coronary disease at the culprit lesion site. However, 
contemporary medical treatment is not lesion or patient specific, largely due to the 
inability to accurately characterise the lesion. Current IVUS-VH data suggests 
significant variations exist in the lipid-rich, necrotic core content of the culprit lesion 
[Surmely, Uemura, Nasu, Fujii et al]. We examined the ability of IVUS-VH as an 
investigational tool in the treatment of coronary artery disease. The work contained 
in this thesis hopes to contribute important knowledge to this growing field and 
examine the clinical utility of IVUS-VH in the field of coronary intervention for 
ACS lesions. 
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2.1.1 The Technology 
As previously described, grayscale intravascular ultrasonography (IVUS) is a 
tomographic imaging tool that can visualise coronary atherosclerosis in vivo, 
elucidating plaque area, plaque distribution, lesion length and coronary remodeling. 
IVUS has demonstrated discrepancies between the extent of atherosclerosis seen by 
coronary angiography and the actual extent of atherosclerotic disease.[Nissen et al 
2001] Angiography or “Lumenography” is able to determine only whether there is 
adequate space for blood to flow well, but it cannot assess the underlying vessel 
changes and “hidden” plaque burden. Quantitative assessment of this plaque 
composition within a lesion has not been possible with grayscale IVUS analysis, 
until now.[Nissen et al 2002]  IVUS-VH uses advanced analysis of ultrasound 
backscatter signals by processing  the power, frequency and amplitude to overcome 
the limitations of grayscale IVUS and provide a detailed analysis of plaque 
morphology.[Nair A et al 2002] In addition, IVUS-VH has the potential to provide 
in-vivo patient-specific plaque analysis to determine the range of characteristics in 
relation to clinical factors and risk, rather than making assumptions from a highly 
selected autopsy population. 
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IVUS-VH                                               Traditional Histology 
Figure 2.1: IVUS-VH Production of a colour map of the atherosclerotic plaque 
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Obviously many different cell and tissue types are commonly found in 
atherosclerotic plaques analysed pathologically. To simplify image interpretation and 
because of the fundamental resolution limitations of the underlying ultrasound 
signal, plaque components are grouped into four basic tissue types during IVUS-VH 
imaging. These components are displayed on the image as different colour pixels. 
This technique is based on advanced radiofrequency analysis of reflected ultrasound 
signals in a frequency domain analysis and displays the reconstructed color-coded 
tissue map of plaque composition superimposed on cross-sectional mages of the 
coronary artery obtained by grayscale IVUS.[Nair et al 2002]  Basic IVUS enables 
real-time, high-resolution tomographic visualization of the coronary arteries. Both 
lumen and vessel dimensions and the distribution of plaques can be analyzed. In 
addition, grayscale IVUS can be used to assess the presence of intraluminal 
thrombus and plaque rupture.[Potkin et al 1990] Grayscale IVUS has demonstrated 
the multiplicity of plaque ruptures seen in patients with ACS.[Tanaka et al 2005, 
Rioufol et al 2002, Schoenhagen 2003] In 2002 a study demonstrated that the 
number of vulnerable plaques with less than 75% luminal obstruction identified by 
IVUS had a positive correlation with future cardiovascular events.[Yamagishi et al 
2000] Of note, serial IVUS analysis of a small patient cohort showed that 50% of 
ruptured coronary plaques detected on first ACS event had spontaneously healed at 
22 months' follow-up.[Rioufol et al 2004] 
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Figure 2.2: Path of the ultrasound signal into the tissue interface (adapted from 
Volcano slide set – permission granted) 
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Figure 2.3: The backscattered ultrasound signal frequency and amplitude related to 
previously known tissue calibration spectra (Adapted from Volcano Corp slideset ) 
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Figure 2.4: The eight spectral parameters taken from the 
ultrasound signal that are used in decision tree for VH tissue types 
 
1
.
. 
2
.
.
. 
3
.
.
. 
4
.
.
. 
5
.
.
. 6
.
.
. 
8
.
.
. 
7
.
.
. 
[70] 
 
May 14, 2007
MHz
dB
BDC
Spectral 
Parameters
MaxP < -25.05
Type: Col lagen
#of RO Is : 5
MaxP > -25.05
Type: Col lagen
#of RO Is : 26
Int < -28.65
#of RO Is : 31
Int < -14.8
Type: Col lagen
#of RO Is : 5
Int > -14.8
Type: Col lagen
#of RO Is : 5
F at MaxP < 21.045
#of RO Is : 10
F at MaxP > 21.045
Type: Col lagen
#of RO Is : 17
MB F < -65.09
#of RO Is : 27
Int < -4.195
Type: Calcium
#of RO Is : 6
Int > -4.195
Type: Col lagen
#of RO Is : 5
MB F > -65.09
#of RO Is : 11
F at MaxP < 30.03
#of RO Is : 38
MaxP < -16.095
Type: Col lagen
#of RO Is : 6
F at MaxP < 34.275
Type: Necr otic
#of RO Is : 6
MB F < -66.66
Type: FibroLipidic
#of RO Is : 5
MB F > -66.65
Type: Col lagen
#of RO Is : 5
MaxP < -12.145
#of RO Is : 10
MaxP > -12.145
Type: Fibro-Lipidic
#of RO Is : 5
F at MaxP > 34.275
#of RO Is : 15
MaxP < -9 .915
#of RO Is : 21
F at MaxP < 35.5
Type: Col lagen
#of RO Is : 8
F at MaxP > 35.5
Type: Col lagen
#of RO Is : 9
MaxP > -9 .915
#of RO Is : 17
MaxP > -16.095
#of RO Is : 38
F at MaxP > 30.03
#of RO Is :  44
Int > -28.65
#of RO Is : 82
MB F < -55.695
#of RO Is : 113
MinP  <-17.915
Type: Col lagen
#of RO Is : 5
MB F < -53.15
Type: Calcium
#of RO Is :  8
MB F > -53.15
Type: Calcium
#of RO Is : 20
MinP  > -17.915
#of RO Is : 28
MB F >-55.695
#of RO Is : 33
146
#of RO Is : 


TREE
ROOT













Classification
Figure 2.5: The process of spectral analysis generating tissue classification 
 
Figure 2.6: Plaque rupture shown angiographically, histologically and on 
IVUS.  
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Figure 2.7 – VH tissue types with examples and descriptions of the 
corresponding histology. 
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 Grayscale IVUS imaging is, however, limited with regards to analysis of plaque 
composition. Both calcified and dense fibrotic tissues, such as those found in 
plaques, have strong echoreflections with lateral shadowing and are, therefore, not 
easy to differentiate. Currently, VH can better distinguish between areas with low 
echoreflection than grayscale IVUS. Nevertheless, quantification of 
hypoechogenicity is important, as it has been related to an adverse event rate. 
[Mathiesen et al 2001, Gronholdt et al 2001] 
2.1.2 Validity 
There have been issues over the best way to validate IVUS-VH as ex-vivo analysis 
removes blood attenuation, ECG gating and coronary contraction/motion. To 
assess validity in-vivo, VH-IVUS backscatter data from 51 ex vivo left anterior 
descending coronary arteries were recorded and compared with histological 
interpretation of the same sites. [Nair A et al 2007] The overall predictive accuracies 
were 93.5% for fibrotic tissue, 94.1% for fibrofatty tissue, 95.8% for necrotic core 
and 96.7% for dense calcium. This demonstrated the potential of this imaging tool 
for the specific analysis of plaque vulnerability. In the Carotid Artery Plaque Virtual 
Histology Evaluation (CAPITAL) study there was a strong correlation between 
plaque characterisation and that following true histological examination of the 
plaque following endarterectomy. [Diethrich et al 2007] The predictive accuracy for 
TCFA was 99.4% and 96.1% for calcified TCFA. In vivo studies using IVUS-VH 
have shown that presumed vulnerable plaques (TCFAs according to IVUS criteria) 
occur more often in patients with ACS than in patients with stable 
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angina.[Rodriguez-Granillo et al 2005] Patients who are stable at clinical presentation 
show more intimal thickening and plaque composition with considerably more 
fibrotic tissue than that typically seen in vulnerable plaques. 
 
Table 2.1: Histological validation of IVUS-VH. 
 
2.1.3Tissue Types  
2.1.3.1 Fibrous 
Fibrous tissue is represented by dark green pixels. Histologically, this tissue is 
collagenous with no lipid. [Burke et al 2002, Nair et al 2007] On grayscale IVUS, these 
tissues tend to be medium-bright regions.  
2.1.3.2 Fibrofatty  
Fibrofatty tissue is denoted in VH by light green pixels. This tissue is loosely 
packed collagen, but it can have a cellular quality with potential for foam cells to 
start invading. [Nair et al 2007] There is usually no necrotic core and even 
cholesterol products are rare. If thrombus or plaque rupture is included as plaque 
during analysis, then it appears as fibrofatty plaque [Murray et al 2009]. 
Sensitivity  Specificity  VH  Plaque  
Component  
Predictive  
Accuracy  %  CI  %  CI  
FT ( n  =  471)  93.5 %  95.7 %  94  – 98  90.9 %  88  – 94  
FF ( n = 130)  94.1%  72.3%  65  – 80  97.9%  97  – 99  
NC ( n = 132)  95.8%  91.7%  87  – 96  96.6%  95  – 98  
DC ( n = 156)  96.7%  86.5%  81  – 92  98.9%  98  – 100  
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Figure 2.8: IVUS-VH characterisation of Fibrous and Fibrofatty lesions 
2.1.3.3 Necrotic core 
In VH the necrotic core is seen as red. This tissue is a mixture of soft, lipid-like 
dead cells, foam cells and trapped blood cells.[Burke at al 2002] Most of any real 
structure is lost and with some areas producing micro-calcification as a by-product 
(from the dead cells) this leads to a recipe for gross instability and rupture with 
friable areas next to sharp calcification. 
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2.1.3.4. Dense calcium 
White pixels represent dense calcium. These calcified regions can be lost during 
histology processing but on plain grayscale IVUS, they act as extremely strong 
reflectors of signal and appear as bright white with a “red” shadow behind. There is 
ongoing debate amongst the IVUS-VH research community about how much 
information can safely be derived behind various types of calcium [Murray et al 
2010]. Stent struts may also appear as calcium, if included in plaque analysis. 
                                                                
Figure 2.9:  IVUS-VH analysis of necrotic core and dense calcium within lesions 
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2.2 How can IVUS-VH improve our knowledge about coronary 
disease? 
2.2.1 Plaque Risk Assessment 
In-vivo plaque classification with VH-IVUS is based on a histopathological 
classification system developed by Virmani et al. in 2000. From this system, coronary 
lesions seen on VH can be classified as adaptive intimal thickening, pathologic 
intimal thickening, fibroatheroma, fibrocalcific and TCFA plaques. For risk 
stratification or the likelihood of lesion rupture, it may be important to distinguish 
between the above-mentioned plaque types. This classification system represents 
the development of atherosclerosis through to atherothrombosis.  
2.2.2 Adaptive and Pathological intimal thickening (AIT) + (PIT) 
In adaptive intimal thickening, the intimal tissue largely comprises smooth muscle 
cells within a collagen matrix. In pathological intimal thickening, the intimal tissue 
comprise of mixed fibrous and fibrofatty plaque (lipid pools) with very little or no 
necrotic core. There can be microcalcification but this occurs in less than 10% of 
the plaque [Nakashima et al 2007]. 
2.2.3 Fibroatheroma (FA) 
Fibroatheromatous plaques have a true necrotic core greater than 10% of total 
plaque volume and this contains cholesterol products. The fibrous cap that protects 
the coronary lumen from the necrotic core is significant. As the lesions progresses, 
the fibrous cap is assumed to diminish to a thickness less than 65 m, which would 
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increase vulnerability and allow classification as a TCFA. The limited resolution of 
IVUS-VH (approx 150 m) means the cap can be measured only if greater than 150 
m thick. IVUS-VH cannot determine true TCFA and therefore VH-TCFA is only 
a surrogate measure and not a definitive term. 
2.2.4 Fibrocalcific plaque 
Fibrocalcific plaques are mainly fibrous plaques that are dense in calcium (>10%) 
and some have a small amount of confluent necrotic core (<10%). Fibrocalcific 
plaques are increasingly found in plaques at advanced stages of development and 
therefore likely represent the late stages of atherosclerosis. [Falk et al 1995] 
 2.2.5 Thin Cap Fibroatheroma (TCFA): The vulnerable plaque. 
TCFA have a confluent necrotic core (>10%) in direct contact with the lumen (no 
evidence of a fibrous cap) and a minor amount of calcium (<10%). If this is present 
on three consecutive IVUS-VH cross-sectional frames, this confers an increase in 
vulnerability. It is currently thought that the higher the extent of surface contact the 
necrotic core has with the lumen, produces the highest risk of rupture. From some 
post-mortem data, a TCFA with a narrow lumen, confluent necrotic core greater 
than 20% at an angle of more than 35 degrees, with speckly calcification and a 
positive remodeling index or high plaque burden confers the most-vulnerable plaque 
[Burke et al 2001]. This appears to be in some ways different from the commonly 
taught theory that non-significant plaques are the ones which are more likely to 
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rupture [Kolodgie et al 2003]. It may simply be that non-significant plaques are just 
more frequent along a given coronary segment. 
 
 
Figure 2.9.1 – Virmani classification of VH Plaque types with examples. 
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Figure 2.9.2 – Flow chart to allow full plaque diagnostics to a histological 
standard using OCT and IVUS-VH. OCT is used to confirm TCFA 
presence. 
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2.3 Can IVUS-VH influence coronary intervention? 
The majority of acute coronary events are triggered by plaque rupture. [Rioufol et al 
2002, Schoenhagen et al 2003] Therefore, defining the anatomic features that lead to 
plaque rupture should be of central importance to lesion imaging. Post-mortem 
analyses have shown that thin-cap fibroatheroma (TCFA) is probably the main 
precursor lesion for plaque rupture.[Kolodgie et al 2004] TCFAs are characterized by 
a large necrotic core separated from the coronary lumen by a thin fibrous cap. 
According to histological studies, the size of the necrotic core and the thickness of 
the fibrous cap have a critical influence on plaque stability. In addition, other 
characteristics of vulnerable lesions include localized expansive enlargement of the 
vessel wall ('positive remodeling') and microcalcification within the lesion. The 
location of the lesion within the coronary tree, the length of the lesion and the 
narrowing of the artery relative to healthy reference lumen size are also important 
parameters for the evaluation of plaque vulnerability. Coronary dimensions and 
elements of plaque composition such as the presence and amount of necrotic core, 
the degree of calcification and coronary remodeling are all anatomic features 
visualized by IVUS and IVUS-VH, but not by traditional angiography. The 
reconstruction of IVUS-VH images in a longitudinal view, enables a comprehensive 
analysis of the total length of the plaque and its complete orientation to the rest of 
the coronary tree. Within this thesis we are concerned with the complete 
understanding and treatment of vulnerable plaque by PCI. Angiography may 
highlight the minimum lumen diameter and allow successful stent placement in this 
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area, but it gives no account of potential positively remodelled, unstable plaque 
lurking within the reference segments. Unfortunately, it is in these reference 
segments that stent edges are placed and therefore this may potentially result in a 
failure to treat all unstable plaque or indeed directly disturb the inflow and outflow 
of the stented segment. Theortically, this may contribute to the previously quoted 
future MACE and repeat revascularisation rate of around 20% in ACS patients 
previously treated with PCI [Eagle et al 2004]. 
 
Figure 2.9.3: Longitudinal view of IVUS-VH pullback showing available 
information. 
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2.4 Investigating the utility of IVUS-VH analysis in ACS. 
The longitudinal IVUS-VH view of the target segment provides detailed 
information about the length of the plaque and its general composition. According 
to post-mortem data, plaque composition is a better predictor of ACS events than 
the degree of coronary stenosis. [Kolodgie et al 2003] The formation of intraluminal 
thrombus after plaque rupture or erosion has a central role in the clinical course of 
ACS. Coronary thrombosis is a dynamic process and the culprit thrombus can 
assume different degrees of organization. With repeated thrombosis, the imaging of 
lesions becomes increasingly difficult. As the plaque ruptures, the lesion site is 
covered with thrombus and the underlying plaque and necrotic core is filled by 
intramural hemorrhage.[Nissen et al 2000] An intraluminal thrombus tail, rich in red 
blood cells, can form proximal or distal to the site of plaque rupture, especially in 
the presence of slow blood flow. Pharmacological therapy at this stage can aid to 
partially clear the thrombotic debris. However, any residual thrombotic tissue can 
become organised over time to become fibrotic tissue, causing luminal narrowing 
further to that at the rupture site. This can only be assessed completely by IVUS-
VH analysis before PCI. 
Post-mortem studies have clearly shown that repeated plaque ruptures have a key 
role in plaque progression. Pathologic studies have detected complex plaques with 
previous ruptures concentrating at one site, suggesting that certain sites are 
chronically vulnerable.[Burke et al 2003] Subclinical episodes of plaque disruption 
followed by healing is considered a mechanism by which plaque burden increases 
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and leads to inward remodelling processes and finally luminal narrowing.[Burke et al 
2001] .The origin or focus of the plaque rupture can be proximal or distal to the 
minimum lumen of the lesion.[Nissen et al 2004] Hence, assessment of 
atherosclerotic lesions should include the whole length of the lesion to ensure 
detection of the site of plaque rupture, which might not necessarily be the site of 
the minimum lumen cross-sectional area. This phenomenon has been seen, but not 
fully investigated earlier in IVUS studies. [Valgimiglii et al 2006]  As a follow on from 
this idea of culprit plaques being remote from the angiographic stenosis, we aim to 
measure the distance between plaque types in our cohort of ACS patients, with the 
hypothesis that different sites within the culprit artery will contain significantly 
different types of plaque. 
 
Figure 2.9.4: Schematic diagram of potential multiple necrotic core positions. 
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In ACS patients, despite pharmacology and early PCI, significant numbers of 
patients have a recurrent event which raises the question of whether procedural 
factors influence the outcome. The mechanism of angioplasty in acute plaques is 
poorly understood [Wei Hu et al 2001]. In a recent first in man paper, Wei and 
Schiele reported in 20 ACS patients undergoing pre-dilatation that 35% of lumen 
enlargement was due to an increase in vessel area and 65% to a decrease in plaque 
area. They concluded that fibrous and fibro-fatty elements re-distribute into the 
reference segments and one third of necrotic tissue was “lost” potentially supporting 
a theory of embolisation. It is possible that in this ACS group that fibrous and fibro-
fatty “plaque” is actually thrombus or thrombo-fibrotic material coded as “fibrous” 
within the VH classification tree. This may suggest that incomplete lesion treatment 
could leave behind either a thrombotic or necrotic burden at the stent edges. For 
this reason, we will image the culprit vessel after stent implantation to ascertain both 
the stent deployment and the prevalence of reference segment or stent edge residual 
disease. Utilising VH observations, we will then be able to analyse this disease to 
assess its relative composition and geometry. 
 
Angiographically guided stent placement is an imperfect but realistic compromise in 
the setting of ‘real world’ PCI. Many subtle forms of stent placement abnormalities 
exist and unfortunately these may contribute to long-term adverse events, such as 
stent thrombosis and in-stent re-stenosis. The S.T.L.L.R (Prospective Evaluation of 
the Impact of Stent Deployment Techniques on Clinical Outcomes of Patient 
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Treated With the CYPHER® Stent) [Costa et al 2005] used QCA evaluation of stent 
placement to show that suboptimal placement (or "geographic miss") is widespread 
and confers a "three times increased chance of heart attack and twice the chance of a 
repeat procedure".  The types of geographic miss range from longitudinal miss with 
the stent being too short or too proximal/distal to cover the lesion, to axial miss 
which means the stent is under/over sized. The use of IVUS-VH before and after  
interventions allows further inspection and measurement of the vessel size, plaque 
length and inspection of side-branch anatomy and plaque constituents (e.g. 
significant calcification) This extra information will form part of our aim to follow 
the patients’ clinical course after discharge to ascertain if it has any impact on future 
MACE or hospitalisation. 
Another area of interest is in the angiographic placement of stents directly into 
necrotic areas of plaque, which are thought not to occur at the MLA of the culprit 
plaque [Hong et al 2007]. Stent struts embedded within necrotic tissue delay 
endothelialisation and adversely effect tissue level homeostasis and thrombotic status 
[Joner et al 2006] This is a very important area where IVUS-VH could positively 
influence stent placement in ACS patients. This would ensure that not only the MLA 
is covered but also the more unstable necrotic shoulder of the distal / proximal 
plaque, which may prevent further late thrombotic sequelae. We therefore aim to 
record evidence within our observational study of whether angiographically guided 
stent placement may cause stent edges to be close or within necrotic core. 
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As post-mortem data have demonstrated, longitudinal analysis of the target lesion 
using IVUS-VH can show the site of plaque rupture which are often proximal to 
the site of the minimal lumen area. As a consequence, only just covering the 
minimum lumen site might not be sufficient to fully treat the site of the problem. 
This could reduce the rate of future events related to reoccurring ruptures of an 
uncovered lesion. The prevalence of stent length to lesion length mismatch will also 
be recorded in our observations with the end point being the absolute rate of 
geographic miss within the culprit lesion. 
 
 
Figure 2.9.5: The theoretical benefits of entire lesion coverage in ACS. 
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2.5 Previous clinical studies assessing and utilising IVUS-VH in ACS 
Recent studies have confirmed that plaque composition has a nonuniform 
distribution along the coronary arteries. [Valgimigli et al 2005] Depending on the 
distance from the coronary ostium, the proximal segments show a significantly 
larger necrotic core, but no change in other plaque components.  As the proportion 
of necrotic core is related to overall lesion vulnerability, these findings could 
explain the higher incidence of plaque ruptures in the proximal segments of the 
coronary tree. 
According to previous studies, IVUS-VH analysis could confirm the relation of 
outward (positive) and inward (negative) remodeling processes to plaque 
composition. In a small, in vivo study, plaque composition and morphology assessed 
using IVUS radiofrequency analysis were shown to relate to coronary remodelling, 
supporting a role of plaque composition in vessel remodelling. [Rodriguez-Granillo et 
al 2006]  The size of necrotic core is significantly larger in lesions with positive 
remodeling; fibrous plaque burden, however, appears to have a significant inverse 
relationship with remodeling index. Positive remodelling is, therefore, associated 
with presumed high-risk lesions such as fibroatheromata and TCFAs, while 
negative remodeling is associated with less-vulnerable lesion types such as those 
with pathologic intimal thickening and fibrotic stable plaques. Recently IVUS-VH 
analyses were performed in the first 990 patients enrolled in the 3,000+ patient 
global IVUS-VH Registry to assess the impact of gender and age on in vivo plaque 
characterization. The 990 patients were divided into 3 age group terciles (<58, 58 to 
[88] 
 
68, and >68 years) and again divided according to gender. Naturally, both women 
and men had an increase in plaque with increasing age and at any age, men had 
more plaque than women. The percentages of dense calcium and necrotic core 
increased with increasing patient age and diabetic status. In both men and women 
and gender differences were lowest in the oldest tercile (>68 years). [Qian et al 2009] 
In December 2008 a group from Korea found no re-flow/slow flow in 12 of 57 
patients (21%) undergoing PCI for ACS. [Bae et al] Having performed pre-PCI 
IVUS-VH they found that fibro-fatty plaque volume across the entire lesion length 
correlated with slow flow which appears to incriminate this type of plaque (or more 
likely thrombus) as the main culprit for reduction in TIMI flow following lesion 
treatment. This suggests that IVUS-VH in ACS can identify angiographically silent 
thrombus burden and potentially facilitate thrombus aspiration before balloon 
angioplasty or stent implantation. However other authors looking at post thrombus 
aspiration STEMI patients and stable angina patients, appear to suggest that only 
the necrotic core volume is the independent predictor of no-reflow. [Hong et al 
2009; Kawaguchi et al 2007; Kawamoto et al 2007]. 
Over time a growing evidence base is accumulating to support optimum lesion 
assessment and stent deployment during PCI procedures, to ensure the clinical 
benefit is passed on to patients. We aim to show within our observational studies, 
the difference between plaque geometry and components in different clinical 
situations and the effect of angiographically guided PCI on lesion outcome (as 
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assessed by IVUS-VH) We hope that the information gained in this area will not 
only enhance our knowledge of unstable coronary disease but provide insight and 
evidence for the continued use of IVUS-VH to improve invasive coronary 
procedures. Our knowledge of the natural history of atherosclerosis including 
lesion classification relies on post-mortem histology data. As IVUS-VH enables in 
vivo identification of four different plaque characteristics and their location, this 
technique may enable a more accurate classification of lesions with regard to 
progression and regression. With time, we may even be able to determine with high 
accuracy which lesions should be treated immediately with intervention and which 
with long-term systemic medical therapy. 
2.6 IVUS-VH Current Limitations 
The limitations of this technique are described elsewhere. [Konig et al 2008]  The 
most crucial aspect of any IVUS examination is a steady pullback. However, 
accurate observer manual border detection is critical when post-processing the 
images. The virtual histology software produces an automated border detection 
which is very variable in its accuracy. Poor detection of vessel landmarks can 
seriously influence composition results and plaque risk assessment. Therefore our 
first study within this thesis aims to fully determine not only the intra and inter-
observer variability of VH analyses but to define the thresholf of measurement 
error for future longitudinal studies in this area. 
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The axial resolution of IVUS-VH (150 m) is too low to detect thin fibrous cap 
thickness, which is currently defined as 65 m. This threshold for critical cap 
thickness has, however, been established for ruptured plaques and not TCFAs. 
Histopathological studies apparently demonstrate a higher thickness for caps in 
TCFAs. [Konig et al 2008] This is related to the dehydration produced when 
preparing specimens. 
As previously discussed and shown, thrombus detection could help localize the 
extent and also origin of the plaque rupture in patients with ACS. Thrombus as the 
primary surrogate for acute coronary thrombosis cannot yet be assigned a colour 
classification and therefore it should be spotted on grey-scale IVUS to ensure it is 
documented within the analyses. More attention should be paid to rupture and 
thrombus associated plaque (TAP) as this effectively represents the ruptured plaque 
that has been involved directly in an atherothrombotic episode. In a similar 
situation plaque rupture is visible on grey-scale IVUS but is not traceable by the 
current software and has to be included within the plaque burden (increasing 
fibrofatty proportions).  
There also remains a concern with regard to the true ability of the IVUS-VH 
classification tree algorithm to accurately predict what is behind areas of significant 
calcification within plaques [Murray et al 2010]. 
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There are evolving techniques using OCT (optical coherence tomography) and 
NIRS (near-infrared spectroscopy) which may help delineate the vessel architecture 
and composition. Optical coherence tomography (OCT) uses near-infrared 
electromagnetic radiation, and cross-sectional images are generated by measuring 
the echo time delay and intensity of light that is reflected or back-scattered from 
internal structures in the tissue. 
Current OCT images are obtained at the peak wavelength in the 1,280–1,350 nm 
band that enables a 10–15 µm tissue axial resolution, 94 µm lateral resolution at 3 
mm, and maximal scan diameter of 6–8 mm (about 10 times resolution as 
compared with IVUS. ‘Lipiscan™’ IVUS has now been cleared for sale in the USA 
and uses NIRS to detect areas of lipid core providing a ‘chemogram™’ linked to 
the IVUS pullback. This NIRS is based upon the different absorption of light at 
different wavelengths by different chemicals. This allows co-registration of 
coronary anatomy and true lipid composition. This technique not only advances 
our knowledge of atherosclerosis but appears to show promise in determining 
which patients may sustain a peri-procedural myocardial infarction. It may also 
become useful in judging the length of stent to place in order to prevent landing 
edges into unstable lipid cores. 
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2.7 Recent large trials in IVUS-VH utility  
2.7.1 Prospect, VIVA, Atheroemo and VIVA sub-studies 
Interestingly, all of these trials (both independent and industry sponsored) have 
reported surprisingly similar results. In patients undergoing coronary angiography, 
the presence of IVUS virtual histology-derived TCFA lesions in a non-culprit 
coronary artery is strongly and independently predictive for the occurrence of 
MACE within 1 year, particularly of death and ACS. Thin-cap fibroatheroma lesions 
with a large plaque burden carry higher risk than small TCFA lesions, especially in 
the short term. 
Moreover, lesions lacking necrotic core (non-fibroatheromatous lesions) were 
found to be clinically stable and were rarely associated with clinical events during 3 
years of follow-up.  
In summary, the common finding from these trials was that the following were 
predictive of future MACE in non-culprit arteries (The culprits were stented before 
IVUS-VH was performed): 
1. Plaque Burden >70% 
2. Presence of TCFA 
3. Minimum Lumen Area <4mm2 
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The most recent trial Atheroemo [Garcia-Garcia et al 2012] confirmed the findings 
of Prospect [Stone et al 2010] and VIVA [Calvert et al 2011]. In >500 patients, 6% 
had a high risk plaque that fits all of thse criteria and these patients had a 10% rate 
of death, ACS or revascularisation at 1 year. This end-point was driven by 
revascularisation events. Unfortunately this trial subdivided TCFA into small and 
large. This is something that was never done before and not within the previous 
guidelines on how to analyse VH [Garcia-Garcia et al 2008]. The lack of hard events 
adjudicated in all these trials is related to the general methodology. Unfortunately 
when a stent is placed in the culprit lesion and non-culprit disease is then imaged 
for follow up, the natural history of this disease process is profoundly attenuated by 
the patients being placed upon DAPT, Statin, ACE and B-blocker in as treatment 
for their culprit event. The only way to study this as a true natural history study 
would be to intravascularly image asymptomatic patients (on no primary 
preventative medication) and follow them up for events. There are serious 
questions about whether this would ever be ethical in the light of current findings. 
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Figure 2.9.6 – Results of Atheroemo study into plaque features 
and subsequent events  
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Figure 2.9.7 – Most recent data on plaque features and % MACE. This 
may allow prognostication and plaque staging in the future. 
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2.8 Counter arguments to the “vulnerable plaque theory” 
The vulnerable plaque theory (like any theory) has lots of issues. Principally, a 
“biologically active” plaque can change over time (possibly even as short as a 
few months). Notwithstanding this major issue, we must start to consider the 
whole problem in more detail and attempt to understand “the perfect storm”. A 
recent review by Renu Virmani and Valentin Fuster et al 2014, has highlighted six 
major areas that can help us map out the array of variables that are responsible 
for these arterial natural disasters. 
1.     Plaque Characteristics (location, endothelial dysfunction, composition, 
vessel remodelling) 
2.     Blood Flow (shear stress, hypertension, viscosity etc) 
3.     Haemostasis (platelet function, tissue factor, PAI-1, thrombin, 
coagulation factors etc) 
4.     Inflammation/metabolic conditions (Infection, CKD, diabetes, 
metabolic syndrome etc) 
5.     Neuro-hormonal (mental stress, depression etc) 
6.     Environmental (diet, smoking, drugs, sedentary lifestyle, extreme exertion 
etc) 
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I would add to this a seventh: Genetics (A genetic pre-disposition that may 
encompass all of the above other factors, but is currently poorly understood).  
2.9 Conclusions and subsequent hypotheses 
IVUS-VH is a promising imaging tool with potential for clinical application in PCI. 
However, several issues have yet to be adequately addressed by the current literature. 
Some of these issues are addressed in our hypotheses for this work. These are as 
follows: 
1. Is the intra and inter-observer measurement variability for the technique (in both 
area and volume analyses) sufficient to allow differences in plaque variables to 
actually be detected? 
2. Are there detectable difference in IVUS-VH plaque variables between culprit and 
stable patient presentations? Can we predict the clinical implications of a plaque 
from morphology alone? Are there site-specific differences in plaque morphology 
across the spectrum  of coronary artery disease? 
3. Does the minimum lumen area of a coronary plaque contain the most vulnerable 
plaque as classified by IVUS-VH? What is the relationship and difference between 
plaque at the MLA and the site of maximum Necrotic Core. 
4. What is the subsequent prevalence of stent abnormalities, geographic miss and 
residual vulnerable plaque when PCI is performed for ACS under angiographic 
guidance?
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3.1  Introduction 
The use of IVUS in the clinical setting has previously been restricted, in our centre, 
to the evaluation of left main stem disease, in-stent restenosis and visualisation of 
indeterminate narrowings or strange angiographic appearances. We sought during 
this study, with ethical approval, to expand the indications for IVUS-VH use to 
encompass the treatment of Acute Coronary Syndrome patients.   
3.1.1  Study design 
The following methods provide the study protocol for the initial investigation 
into the use of virtual histology in the observation of acute coronary syndromes. 
This study protocol has been designed as a single centre, prospective, 
observational cohort study.  
3.1.2 Specific research objectives 
A comprehensive background to the field and literature review has been presented in 
the previous chapters. The specific research objectives of this thesis are to examine 
the use of virtual histology in four specific areas. 
1) The intra- and inter-observer variability of plaque compositional measurements. 
2) The quantification and difference in plaques types across the spectrum of 
coronary artery disease. Can these generate a plaque risk model? 
3) The measurement of the distance and compositional differences between the 
angiographic culprit stenosis and the most unstable plaque in the target vessel 
seen on virtual histology. 
[101] 
 
4) The observation of angiographically guided stent placement and the rate of failure 
to treat unstable plaques and to gain good stent results. 
 
3.1.4 Sample size calculation 
Using the hypothesis that the mean necrotic core volume will be variable between 
the three groups and based upon data from our interim analysis showing a large 
mean SD for volumetric plaque components of +/- 30mm3 a sample size of 70 ACS 
lesions and 50 comparator lesions (non-culprit and stable) has been calculated. From 
this we can expect 80% power to detect a 10mm3 difference in plaque components 
with a 95% confidence interval. This will permit the relative differences in the mean 
of these continuous variables to be calculated using a one-tailed t test between the 
ACS group and the stable angina control group. A p-value of <0.05 will be 
considered significant. 
3.1.5 Statistical analysis 
The clinical, procedural and IVUS-VH data were analyzed using Stats Direct 
statistical software (version 2.7.7). The continuous variables were expressed as mean 
± SD and the categorical data were expressed as proportions. Continuous data were 
compared using Student’s t-test for normally distributed data and a Mann–Whitney 
U test for skewed data. Intra-individual comparisons were performed using the 
Wilcoxon test. Comparison of categorical data and frequency of occurrence was 
performed with Fisher’s exact test. A P value of less than 0.05 was considered 
statistically significant.  
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3.1.6 Protocol Development 
 
Protocol development for this study began in August 2007 between SM and NDP 
after extensive literature analysis and previous background work in the field (NDP). 
The final draft was accepted through the hospital research development committee 
in 2008 and also was processed through the local ethics committee at that time. 
Following discussion with Prof G Hart at the University of Liverpool, an 
amendment was made to the protocol and this was then accepted and registered for 
the degree of MD. The protocol revision was passed by the regional ethics 
committee thereafter in 2008. There was a delay of around one year during this 
process due to political issues at the University which substantially affected the flow 
of the study in terms of initial recruitment. 
3.2 Ethical approval 
 
3.2.1 Good clinical practice 
The study was conducted in compliance with accepted standards of the International 
Conference on Harmonisation Good Clinical Practice guidelines, and conformed 
with all national and local laws, rules and regulations relating to study conduct.  The 
protocol was approved by the local Cheshire Research Ethics Committee. 
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3.2.2 Informed consent 
During the patient visit an unambiguous written patient information sheet in simple 
language was provided, with sufficient time to fully read this information.  The study 
was then discussed in greater detail, allowing for specific questions and providing 
additional information regarding the study.  Each potential subject was adequately 
informed of the aims, methods, anticipated benefits and potential risks of the study 
and any discomfort it may entail.  Patients were informed of their liberty to abstain 
from participation in the study and freedom to withdraw consent to participation at 
any time.  Freely given written informed consent was obtained from all subjects 
before enrolment. A further verbal consent was taken in all patients on entering the 
cardiac catheterisation lab to ensure they still agreed on IVUS examination of their 
coronary arteries before and after the procedure. See Appendix for consent form. 
3.2.3 Confidentiality 
Patients were assigned an individual participant number immediately after providing 
written informed consent and database details were cut to hospital number, initials 
and age in years.  All other electronic documents pertaining to personal data, study 
protocol and results were stored securely by the investigator on home and laptop 
personal computers, solely accessible by the investigator and password protected. 
 
 
[104] 
 
3.2.4 Monitoring 
Continuous monitoring was undertaken throughout by supervisors Dr ND Palmer, 
Dr RH Stables and Prof G Hart.  The study was subject to review at any time by the 
Cheshire Research Ethics Committee. 
3.2.5 Amendments 
A notice of amendment was submitted to the Research Ethics Committee in the 
event of any substantial amendment to the protocol. Full approval was gained from 
the committee chair before further continuation of the study 
3.3  Inclusion Criteria 
 
1. Active acute coronary syndrome requiring PCI. 
2. Able to provide informed consent. 
3. Coronary anatomy suitable for IVUS introduction and pullback. 
 
 
3.4  Exclusion Criteria 
 
1. Significant angiographic left main stem disease. 
2. Significant vessel calcification. 
3. Significant three vessel disease. 
4. Cardiogenic shock or left ventricular failure. 
5. Acute or chronic renal impairment (Creat>200). 
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6. Reduced flow (TIMI II) in the culprit vessel. 
7. Heavy thrombus likely to embolise on passage of IVUS. 
8. Previous PCI in the culprit vessel. 
 
3.5 General Procedural Methods  
 
We performed IVUS-VH analysis along defined proximal coronary segments 
incorporating the entire lesion prior to PCI using motorised (0.5mm/sec) pullbacks. 
Each segment for study was greater than 20mm in length to enable sufficient 
acquisition of data per segment and therefore replicate the current research and 
clinical application of IVUS-VH in lesion assessment. The same data was analysed 
off-line at an interval of two weeks by one independent operator (A+B) to compare 
for intra-observer variability and once by a second independent operator to compare 
for inter-observer variability (C). Individual regions of interest (ROIs) will be 
selected by the operator, guided by agreed anatomical landmarks such as side-
branches or localised calcium deposits. Automated, followed by manual, lumen and 
vessel contour detection is performed by each operator prior to computer-based 
calculation of plaque constituent and plaque/vessel volumes, expressed as mm3.  
 IVUS-VH analysis of a culprit vessel containing a lesion (which is thought to be 
clinically and angiographically the cause for ischaemia and infarction in ACS) 
deemed suitable for PCI and an angiographic non-culprit (unlikely to be responsible 
for ECG changes or ischaemia) lesion was undertaken in ACS patients (n=100 
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lesions). Lesions identified for PCI in elective patients with stable angina were also 
studied in a similar way (n=35 lesions). The three groups were compared with 
respect to measurements of remodelling index (RI), total plaque volume in mm3 and 
the volumes and percentages for the individual plaque components: Fibrous; Fibro-
fatty; Dense Calcium and Necrotic Core.  
 Each culprit lesion was also analysed from a predefined point within the distal 
reference segment to a similar position within the proximal reference segment. The 
length of the segment incorporating the culprit lesion was measured using computer-
generated calipers incorporated within the IVUS-VH system. Along the length of 
each lesion, each IVUS-VH individual frame was analysed. Necrotic core was 
identified by the IVUS-VH classification tree and felt to be significant if it is 
responsible for >20% of the plaque. Over a number of frames the maximum point 
of the necrotic core (NC) was selected, defined as the IVUS cross-section with the 
largest area of confluent necrotic core expressed as a percentage. Finally the distance 
from the maximum NC site to the MLD site was measured in mm. A direct 
comparison was made between the MLD site and maximum NC site, which will 
include the relative constituents of all four plaque components, total plaque burden 
and the remodelling index.  
The selection of non-culprit plaques was operator determined and in 16 cases these 
lesions were interrogated distal to the site of a culprit plaque (same vessel). Four 
non-culprit plaques came from a different (non-culprit) vessel. 
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Comparisons of IVUS and IVUS-VH analysis before and after stent deployment 
were also undertaken. In accordance with conventional clinical practice, operators 
had the option of utilizing the grey-scale IVUS to determine vessel size and 
therefore stent size selection. However, IVUS-VH information regarding lesion 
composition and length was not made available, as this was not a conventional 
clinical application during PCI in our institution. Following stent deployment and 
angiographic evaluation, a further blinded IVUS-VH assessment was undertaken to 
assess stent deployment and geographic miss. Particular importance was placed on 
the distance in mm from stent edges to sites of proximal and distal necrotic core. 
This required accurate determination of proximal and distal anatomical segment 
markers in the initial phase of the study protocol with which to reproducibly 
determine accurate distances to necrotic core and stent edge sites. 
Therefore, the first blinded IVUS-VH determined the lesion length and sites of 
necrotic core rich vulnerable areas. The second blinded (post-stent) IVUS-VH 
determined whether the angiographic stent strategy had:  
1. Covered the full length of the culprit plaque and adjacent vulnerable areas. 
2. Covered all sites of lumen reduction with plaque burden >40% 
3. Adequately expanded the stent to MUSIC and AVID criteria. 
4. Measure the length and dimensions of residual uncovered plaque. 
5. Calculate the prevalence of unstable plaque left behind. 
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3.5.1 Statistics 
We compared relative distances in mm between the stent edges and necrotic core 
sites or residual plaque. Comparisons were also made between the proportions of 
stents that provide complete lesion coverage and those that leave plaque or 
unstable disease uncovered (described as percentages). In the stent group that 
failed to cover disease or adequately deploy, an analysis of the mechanism was 
undertaken i.e. proportions with stent length underestimation, stent 
misplacement, underexpansion or a combination of these factors. Simple 
descriptive statistics were employed. An unpaired t test was made to compare the 
angiographic stent length selection in mm against the subsequent IVUS-VH 
based full lesion length in mm.  
A more detailed statistical methodology is included during each chapter to 
remind the reader of what was done at each investigative stage. 
3.6 Recruitment 
3.6.1 Methods 
Patients suitable to participate in the study were identified by screening the transfer 
lists for urgent PCI. Each patient who was transferred from a district general 
hospital had a referral form detailing their presentation, ECG changes, diagnosis and 
in some cases, diagnostic coronary angiograpy. Further suitability was taken from 
existing case notes and inclusion and exclusion criteria were directly applied at this 
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stage.  Following a formal approach, the nature of the study was verbally explained 
and patients were asked if they were interested in participating.  Those expressing an 
interest were invited to read the patient information leaflet and then re-approached 
for informed consent. 
3.6.2 Limitations 
Recruitment was a challenge for a number of reasons. Many patients being 
transferred had an extensive cardiac history including various exclusion criteria. 
Many patients were not keen to undergo any further procedures than were absolutely 
necessary (in the circumstances). Many patients, after enrollment, were subsequently 
found to have anatomy unsuitable for IVUS such as: heavy thrombotic load, 
significant left main stem disease, heavy calcification and surgical 3VD. In some 
cases, the IVUS would not pass the culprit lesion. Occasionally on passing the IVUS 
catheter, significant ECG ischaemia and symptoms of chest pain, meant the IVUS 
had to be abandoned in favour of urgent PCI. Following completion of the case, 
there were further technical factors related to problems with pullback quality. A 
number of pullbacks were of poor quality and unable to provide meaningful data. 
Media related issues also occurred related to capture of virtual histology data and the 
ability to analyse the data on the given software. A breakdown of the recruitment is 
shown in fig 3.1 below.
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Figure 3.1: Flow diagram of recruitment with patient/lesion numbers.
70 culprit lesions in ACS 
20 non-culprit lesions in 
ACS (16 same vessel) 
35 stable angina lesions 
=125 total lesions in 105 
patients 
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Chapter IV 
Study I 
The intra and inter-observer agreement of IVUS-VH 
analyses for qualitative and quantitative lesion 
assessment. 
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4.1  Introduction 
Coronary plaque imaging with Virtual Histology (VH) allows estimation of the 
quantitative composition of atherosclerotic plaques in-vivo and has already been used 
as a surrogate outcome measure [Serruys et al 2008]. However, there is currently no 
consensus on appropriate VH endpoints for clinical trials or for accurate power 
calculations, to ensure a true difference is being detected. Repeat measurements of 
plaque composition can be subject to both reproducibility (inter-catheter and inter-
pullback) error and variability (human measurement) error - introduced in the 
following ways: 
• Inconsistent definition by the operator of the surfaces to be measured (lumen, 
vessel). 
• Inconsistent selection of the segment to be measured (proximal and distal marker 
frames). 
• Difficulty in distinguishing plaque margins, for example blood from thrombus and 
tissue. 
• Difficulty in distinguishing plaque components such as calcification from adventitia 
or artefact.  
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Figure 4.1: An example of differing IVUS-VH border detection between 
operators. 
Recent serial clinical IVUS-VH studies, such as the IBIS-2 trial [Serruys et al 2008] 
have revealed only small changes in plaque volume and its relative composition 
following pharmacological intervention. The measurement variability of volumetric 
IVUS-VH analyses is therefore an important scientific issue. In the past there has 
been a distinct lack of published literature documenting variability or reproducibility 
for volumetric IVUS-VH measurements in the clinical setting [Hartmann et al 2008; 
Huisman et al 2010; Prasad et al 2008]. Previous validation studies have been confined 
to single frame area analysis or volumetric analysis in pre-defined, short coronary 
segments with mild disease in stable patients. These patients were generally not 
scheduled for coronary intervention [Rodriguez-Granillo et al 2006]. To date, 
assessments of the level of agreement have been based upon calculating the paired 
differences in data and applying a token rule of less than 10% difference in mean 
values as being clinically acceptable. This does not take into account the inherent 
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standard deviation within the data which has a dramatic effect on final numerical 
calculations of individual plaque measurements. 
The knowledge of the observer variability of any measurement is essential for 
validation of scientific techniques and in this case, it is required to ensure a high 
predictive accuracy in serial plaque measurement and composition.  
Therefore, in this study, we assessed the intra and inter-observer variability of 
individual plaque areas, volumes and segment length selection in a single pullback of 
acute coronary syndrome plaques. We utilised a selection of detailed statistical tests 
of measurement error including the repeatability co-efficient. Our aim was to 
comprehensively determine the limits of human variability error for this proposed 
clinical tool. 
4.2 Methods 
This was a single centre, prospective, observational study that received ethical 
approval from a regional National Health Service (NHS) ethics committee in the 
UK. Patients presenting with ACS gave written informed consent and were studied 
prior to percutaneous revascularisation. IVUS-VH imaging of the culprit lesion (CL) 
was undertaken using a phased array catheter (EagleEye catheter, 2.9 F/20 MHz; 
Volcano Corp). Marker frames were chosen in keeping with a consensus document 
on how to analyse both IVUS and VH [Garcia-Garcia et al 2009; Di Mario et al 1998; 
Mintz et al 2001].  The IVUS transducer was advanced beyond the presumed culprit 
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lesion and beyond the next distal side-branch which would be used as a marker for 
localisation during IVUS image assessment. A proximal border for image assessment 
was established in a similar fashion using another side branch or the mouth of the 
guide catheter.  Following administration of 1mg of Isosorbide Dinitrate (ISDN) 
intra-arterially, a continuous motorized pull-back at 0.5 mm/s was performed 
(Volcano R100 pullback device) until the probe had passed the proximal segment 
marker. The plaque composition and other analyses were performed by off-line 
IVUS-VH analysis (S5i Tower and PC VIAS 3.0.394 software; Volcano Corporation) 
following manual adjustment of border contours. The data were analysed off-line at 
intervals of two weeks by two independent operators (SM and NDP), to compare 
for intra (SM1 and SM2) and inter-observer variability (SM1 and NDP).  
Segment length was initially determined by the operator choice of distal and 
proximal VH reference frames. This decision was made after consultation of 
angiographic images (if required), the grey-scale IVUS runs and a written description 
of the pullback segment markers. Short pullbacks (<10mm) or pullbacks containing 
significant calcification or large side-branches (obscuring adequate vessel delineation) 
were not included in the final analysis. Thrombus-laden or ruptured plaques were 
included, as they are a common feature in high risk ACS patients. A separate cohort 
of high risk ACS lesions with a fixed length (n=300 frames) were also individually 
analysed by each operator to provide comparative data on area and volume 
calculations from a fixed length model. Following individual observer manual 
[117] 
 
adjustment of borders in keeping with previous consensus statements, plaque 
variables and constituents were then calculated by the VH algorithm over the entire 
length of a lesion [Von Birglen et al 1997]. Data was collected to include: Lumen area; 
Vessel area; Plaque area; Media area; Fibrous (F); Fibro-fatty (FF); Necrotic core 
(NC); Dense calcium (DC) area are as well as total plaque burden. The total volume 
of fibrous (F); fibro-fatty (FF); dense calcium (DC) and necrotic core (NC) plaque 
was also quantified in mm3. The technique and validation of IVUS-VH has been 
described elsewhere [Garcia-Garcia et al 2009; Nasu et al 2006/2008; Nair et al 
2002/2007] and in a single human study, histological verification has shown accuracy 
[Nasu et al 2006].   
4.3 Statistical Methods 
There are limited previous studies discussing the calculation of power for variability 
analyses. In 2008 Bartlett et al published a paper focussed purely on measurement 
errors in continuous variables; we used the statistical methods from this to calculate 
our provisional limits of agreement for each measurement involved in this work. 
Using necrotic core data from our first 5 patients, the mean of the paired difference 
was 0.74mm3 with a standard deviation (SD) of +/- 0.82mm3. To calculate the limits 
of agreement for a Bland Altman plot of variability we used these results in the 
previously verified formula [Bland et al 1986; Altman et al 1991]. 
Limits of Agreement   =   mean difference +/- 1.96 x SD 
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From these data, the worked limits of agreement are from -0.867 to 2.34mm3. To 
calculate the standard error of these limits and the subsequent 95% confidence 
intervals (CI), we used our standard deviation and n=5 in the formula: 
Standard error     = 1.71 x SD√(n) 
This produces a standard error of 0.63 and in turn 95% CIs of (-2.09, 0.36) and 
(1.12, 3.58) respectively. This data for five patients produces a standard error of 0.63 
which is reduced to 0.31 by increasing the sample size to 20 patients (assuming the 
SD remains relatively constant). A standard error of 0.31 ensures 95% confidence 
intervals around our limits of agreement, which is also within the previously 
acceptable Bland Altman variability of 10%.  
4.3.1 Intra-class correlation co-efficient 
A 10% variability limit, as in previous studies, without considering the inherent 
standard deviation and the limits of agreement, under-estimates error. Therefore, we 
have chosen to calculate the intra and inter-observer agreement using intra class 
correlation co-efficient (ICC) as well as displaying the overall within subject standard 
deviation (WSSD). ICC was used over Kappa because our data is mainly continuous. 
ICC is effectively equivalent to a weighted Kappa statistic [Bonett et al 2002]. We have 
included Bland-Altman plots for visual illustration of variability. Optimal sample 
sizes for ICC are based on the desired power level, the magnitude of the predicted 
ICC and the lower confidence limit. Bonnett et al in 2002, investigated sample size 
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issues for ICC, concluding that the optimum sample size is a function of the size of 
the ICC and the number of ratings per subject, as well as the desired significance 
level (alpha) and desired width (w) of the confidence interval. Bonnett concluded 
that the optimal sample size for two ratings varied from 15 for ICC=.9 to 378 for 
ICC = 0.1. Our sample size of 20 is therefore adequate in this context. 
4.3.2 The repeatability co-efficient 
In order to find the maximum magnitude of measurement error during the analysis 
of these cases, we expanded our analysis to include the repeatability co-efficient 
(RCO). This is calculated from the within subject standard deviation as follows: 
                                            RCO = √m Z (xw) 
Where m is the number of observations per subject, Z is a quantile from the 
standard normal distribution (usually taken as the 5% two tailed quantile of 1.96) and 
Xw is the estimated within-subjects standard deviation (calculated previously). 
The repeatability coefficient (RCO) is a precision measure. It can be thought of as a 
confidence interval for error. It represents the value, below which, the absolute 
difference between two repeated tests results may be expected to lie, with a 
probability of 95%. This is the definition adopted by the British Standards 
Institution [BSI BS5497 1979]. We can therefore say that 95% of our potential future 
measurement errors, in this cohort, should not be beyond the figure calculated by 
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the RCO.  Therefore, any change greater than this level is likely to represent a true 
change in the measured variable of the plaque. 
4.3.3 Statistical analysis 
Statistical analysis was performed using the agreement function within Stats Direct 
statistical software version 2.7.7. Quantitative data are expressed as mean ±1SD or 
within subject standard deviation (WSSD) in mm, mm2 or mm3. The repeatability 
co-efficient is presented as a calculated area or volume in mm2 or mm3 and is also 
expressed as a proportion of the total measured area or volume. Bland Altman plots 
provide a visual display of the agreement within ±2SD of the mean between 
measurements. An intra-class correlation co-efficient of >0.90 is considered 
excellent indicating that less than 10% of the error is due to operator variability. 
4.4 Results 
20 lesions from 20 patients generated 1080 frames of IVUS-VH. Each frame was 
analysed three times (SM1, SM2, NDP) n=3240. A further 300 fixed frames were 
analysed twice (SM1, NDP) to provide data on individual area and volume variability 
from a fixed length. Therefore, a total of 3840 frames were analysed on both the S5i 
platform and PC VIAS 3.0.394.  
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4.4.1 Patient Characteristics 
The basic patient clinical data is documented below in table 4.1. 
Table 4.1: Patient clinical characteristics 
Characteristic Prevalence Value or Percentage 
Age(±SD) 61.2 (±9.7) 
Male 80% 
LAD/Diagonal 42.3% 
RCA 36% 
Circumflex/OM 21.7% 
NSTEMI 60% 
STEMI (Thrombolysed) 16% 
ACS 24% 
Mean Troponin µg/ml (±SD) 12.14 (±24.4) 
Median Troponin µg/ml (IQR) 1.4 (0.04-13.7) 
Local modified TIMI Risk Score 8.5 (±2.3) 
Hypertension 64% 
Diabetes 24% 
Current Smoker 36% 
Ex-smoker 16% 
Family History CAD 60% 
Hypercholesterolaemia 44% 
CKD 4% 
Previous MI 12% 
Previous PCI 0% 
Previous CABG 0% 
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4.4.2 IVUS-VH analysis and data 
The mean segment length analysed in this study was 27.14±9.1mm, (range 13 to 
45mm). The results of these analyses are presented in tables 4.2-4.4 and displayed 
graphically with Bland Altman plots of inter-observer variability (figure 4.1). The 
details of the separate individual area analyses and fixed length volume analyses are 
displayed in table 4.5. 
Table 4.2: Calculated observer means ± Standard Deviation (SD), per 
variable. 
 
 
*SM=Observer 1; NDP=Observer 2. 
Vessel Variable  SM(1)* Mean ±SD SM(2) Mean ±SD NDP* Mean ±SD 
Segment Length (mm) 27.02±9.1 27.29±8.7 27.12±9.4 
Total Plaque Volume (mm3) 212.63±103 212.68±102.9 212.90±103.6 
Fibrous Volume (mm3) 78.99±38.9 79.66±39.2 79.40±39.8 
Fibro-fatty Volume (mm3) 15.13±8.6 15.73±8.7 16.05±9.1 
Necrotic Core Volume (mm3) 29.10±32.3 28.93±32.1 28.51±32 
Dense Calcium Volume (mm3) 14.68±18.8 14.62±18.6 15.03±18.3 
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Table 4.3: Paired differences between individual observers and the relative 
percentages of the variable total. 
 
Vessel Variable 
 
SM (1+2) Mean ±SD NDP Mean ±SD Paired Difference 
±SD (% total) 
Segment length (mm) 
 
27.2±8.9 27.1±9.4 0.1±0.5 
(0.36 %) 
Total plaque volume (mm3) 
 
212.66±103 212.90±103.6 0.24±0.6 
(0.11%) 
Fibrous volume (mm3) 
 
79.33±39.1 79.40±39.8 0.07±0.7 
(0.09%) 
Fibro-fatty volume (mm3) 
 
15.43±8.7 16.05±9.1 0.62±0.4 
(4%) 
Necrotic vore Volume (mm3) 
 
29.02±32.2 28.51±32 0.51±0.2 
(1.8%) 
Dense calcium volume (mm3) 
 
14.70±18.7 15.03±18.3 0.33±0.4 
(2.2%) 
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Figure 4.2:  Bland-Altman plots for the variables measured between different 
operators with solid lines representing the 95% limits of agreement.  
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Table 4.4: Observer measures of agreement, precision and repeatability with 
the relative percentages of the variable total. 
 
                                             INTRA-OBSERVER                          INTER-OBSERVER 
Vessel   ICC*  WSSD¥ 
(% total) 
 RCOδ 
(%total) 
 ICC WSSD 
(% total) 
  
RCO 
(% 
total) 
Segment length (mm) 0.986 1.01 
(3.7%) 
2.81 
(10.3%) 
 0.96 1.74 
(6.4%) 
4.82 
(17.7%) 
Plaque volume (mm3) 1 1.2 
(0.56%) 
3.32 
(1.6%) 
 0.997 5.59 
(2.6%) 
15.51 
(7.3%) 
Fibrous volume (mm3) 0.998 1.85 
(2.3%) 
5.12 
(6.5%) 
 0.993 3.14 
(4%) 
8.71 
(11%) 
Fibro-fatty volume (mm3) 0.969 1.49 
(9.7%) 
4.13 
(26.8%) 
 0.947 1.99 
(12.9%) 
5.52 
(35.8%) 
Necrotic core volume (mm3) 1 0.37 
(1.3%) 
1.04 
(3.6%) 
 0.994 2.42 
(8.3%) 
6.71 
(23.1%) 
Dense calcium volume (mm3) 1 0.26 
(1.8%) 
0.73 
(5%) 
 0.974 2.89 
(19.7%) 
8.01 
(54%) 
 
*ICC – intra-class correlation co-efficient; ¥ WSSD – within subject standard deviation; δRCO – 
repeatability co-efficient. 
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Figure 4.3: The magnitude of the repeatability co-efficient error between 
observers. 
 
4.4.3 Segment length 
Despite this being an operator based judgement where large amounts of variability 
could be introduced; the ICC remained above 0.90 at 0.986 for intra-observer and 
0.96 for inter-observer. However, this equated to a RCO of 2.81mm for intra and 
4.81mm for inter-observer. This represented 10.4% and 17.4% of the total segment 
length analysed. For comparative assessment, the results from a fixed length 
assessment of 300 frames (147.9mm) are also displayed within table 5. 
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Table 4.5: Fixed length Inter-Observer measurement of 300 VH frames 
Variable 
Mean 
(mm2 or 
mm3) 
Observer 1 
(SM) ±SD 
Observer 2  
(NDP) ±SD 
Paired  
Difference 
±SD 
(%total) 
ICC 
*    
WSSD ¥ 
(%total) 
RCO δ 
(%total) 
Lumen Area  
 
 
6.58±4.1 
 
6.24±3.4 0.34±0.7 0.96 0.74 
(11%) 
2.06 
(31.3%) 
Vessel Area 
 
 
14.99±6.17 
 
14.98±6.13 0.01±0.04 0.99 0.78 
(5%) 
2.1 
(14%) 
Plaque Area 
 
 
8.41±3.94 
 
8.75±4.42 0.34±0.48 0.94 1.05 
(12%) 
2.92 
(33.3%) 
Media Area 
 
 
2.95±0.64 
 
2.96±0.59 0.01±0.05 0.92 0.17 
(5.7% ) 
0.48 
(16.2% ) 
Plaque 
Burden % 
 
56.46±15 57.39±14.28 0.93±0.72 0.94 3.72 
(6.5%) 
10.31 
(17.9%) 
Fibrous 
Area 
 
2.55±1.46 
 
2.77±1.69 0.22±0.23 0.86 0.59 
(21.3%) 
1.64 
(59%) 
Fibro-fatty  
Area 
0.32±0.34 0.35±0.34 0.03±0.00 0.72 0.18 
(51.4%) 
0.49 
(140%) 
Necrotic 
Core  
Area 
1.73±0.62 1.83±0.74 0.1±0.12 0.96 0.18 
(9.8%) 
0.39 
(21.3%) 
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Dense 
Calcium 
Area 
0.86±0.83 0.84±0.84 0.02±0.01 0.98 0.10 
(11.6%) 
0.29 
(33.7%) 
       
Fibrous 
Volume 
 
82.39±41.3 83.15±44.05 0.76±2.75 0.99 2.94 
(3.5%) 
8.14 
(9.9%) 
FibroFatty 
Volume 
 
9.65±5.8 10.45±6.17 0.80±0.37 0.87 2.03 
(19.4%) 
5.63 
(53.8%) 
Necrotic 
Core 
Volume 
54.77±44.8 54.98±45.6 0.21±0.8 0.99 1.36 
(2.5%) 
3.78 
(6.9%) 
Dense 
Calcium 
Volume 
25.87±18.4 25.22±17.7 0.65±0.70 0.99 0.89 
(3.4%) 
2.49 
(9.6%) 
*ICC – intra-class correlation co-efficient; ¥ WSSD – within subject standard deviation; δRCO – 
repeatability co-efficient. 
 
4.4.4 Total Plaque Volume 
Results for this variable (along with % plaque burden – table 4.5) show how heavily 
diseased our analysed segments were. The actual variability between operators was 
small considering the amount of plaque. ICC was greater than 0.99 for both intra 
and inter-observer, with paired differences between operators of only 0.24±0.6mm3. 
This represents only 0.1% of the total plaque volume. However, due to the wide SD 
and resultant 95% limits of agreement, the repeatability error between operators is 
calculated at 15.51mm3 (7.3% of total plaque volume). This error is reduced to 
3.32mm3 (1.6%) by single operator repeat analysis.  
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Figure 4.4: The repeatability co-efficient as a percentage of the total 
measured plaque between observers. 
 
4.4.5 Composition 
IVUS-VH assessments of composition were highly correlated in the majority of 
plaque variables with ICC>0.92 (i.e. less than 8% error between operators). From 
our fixed data in ACS lesions - Fibrous area (ICC=0.86); Fibro-fatty area (ICC=0.72) 
and Fibro-fatty volume (ICC=0.87) show less agreement between operators and this 
appears to be related to the placement of luminal borders around soft plaques and 
thrombus. It is also clear that one of the reasons for the large limits of agreement 
and repeatability co-efficient is the large SD of the data. This is secondary to the 
large spread of plaque values and the large variation seen between individual plaque 
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components. The relevant results for plaque composition are displayed in tables 4.2-
4.5 and figures 4.2-4.3. 
4.5 Discussion 
We have investigated and reported the intra and inter-observer variability for 
volumetric virtual histology analyses, in coronary lesions implicated in an acute 
coronary syndrome presentation. From the results, it is clear that variability in 
segment length selection between operators exists. This is one of the most important 
limitations of IVUS technology and serial studies in the “real world” (as reliance is 
placed on local landmarks such as side branches and calcium deposits). Moreover, 
assessing a long segment of disease requires analysis of multiple serial tomographic 
slices recorded during a pullback sequence. These slices must be manually corrected 
by the individual and the area of the lumen and external elastic membrane (EEM) 
must be traced accurately to ensure viable results. Although the ICC appears to state 
that our variability error for tracing lumen and vessel areas is acceptable between 1-
4% (ICC 0.99-0.96), when calculating the more quantifiable RCO, we appear to have 
differences between operators up to 14% for vessel area and 31% for lumen area.  
Interestingly, the analysis of 300 individual frames between operators has revealed 
significant differences with regard to plaque areas (see table 4.5). Although the 
paired difference of the mean appears very small (as documented in other studies) by 
calculating the within subjects standard deviation and repeatability co-efficient, we 
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see that maximum error levels for fibro-fatty plaque area can be greater than the 
measured area itself (RCO=0.49mm2 = 140% of the fibro-fatty area 0.32mm2).  
Although on first consideration the inherent variability of volume measurements 
should be higher as subsequent area errors are multiplied by length, the opposite 
appears to be true. Volume measurements appear to “smooth out” the individual 
frame errors over the length of the lesion. This could be because one operator may 
measure a greater area than the other operator in one frame, but the reverse may be 
true on the next and over a large lesion this may balance out some of the volume 
variability. This is the first report to highlight that there could be a regression-type 
phenomenon within the values seen for volume measurement error. 
In our cohort, the use of fixed length analysis improved the errors seen in the 
measurement of necrotic core and dense calcium components. However, the 
measurement of fibrous and fibro-fatty components did not change greatly and this 
may be due to the severe nature of the plaques analysed with thrombus, plaque 
rupture and difficult luminal border interpretations. The main source of error in all 
of these cases is a direct reflection of the difficulties in selecting the true lumen-
blood interface (fibrous and fibro-fatty plaque calculations). ACS plaques have a 
high thrombus burden (usually coded as fibrofatty plaque in VH) and this has 
affected our ability to distinguish blood-speckle from true plaque or thrombus. 
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Despite the above results and as in previous studies [Hartmann et al 2009; Huismann et 
al 2010; Prasad et al 2008], the classical markers of agreement such as ICC and paired 
difference of the mean, prove that basic IVUS-VH data can be well matched. Our 
ICC correlation is in keeping with all previously published results, including a recent 
multi-centre IVUS-VH reproducibility registry [Huismann et al 2010] which reported 
values of ICC>0.9 for all plaque components and total plaque volume. These results 
were in mild-moderately diseased coronary segments without a culprit stenosis and 
this is clear when comparing the maximum total plaque volume and maximum 
necrotic core volume between their study (A) and ours (B): A - TPV 91.9±27.3; NC 
9.2±8.8. B - TPV 212.66±103; NC 54.98±45.6.  
It appears from these figures that we have examined the severe end of the spectrum 
of coronary disease with necrotic core and plaque volumes being up to six times 
greater, from relatively similar pullback lengths. There is no doubt that with 
increasing plaque burden comes increasing standard deviations and subsequently 
statistical variability errors. 
The previous benchmark reproducibility and variability study was performed in 15 
patients undergoing IVUS-VH before PCI. In this study from 2006, Rodriguez-
Granillo et al, used two independent observers from a well established core-lab and 
focused on geometrical and compositional elements of IVUS-VH output and 
reported “acceptable reproducibility with less than 10% error”. They published the 
limits of agreement around the measurement of necrotic core area. An inter-
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observer range between +0.16mm2 and -0.20mm2 was seen, indicating a potential for 
maximum error values of around 0.36mm2 for necrotic core across individual frame 
analyses (between operators). This is very similar to what we have calculated with the 
RCO for necrotic core area (0.39mm2). Although this inter-observer variability 
appears reasonable and suggests an overall mean 6% change in necrotic core area 
measurement, if it were applied to a 50 frame volume analysis, then it may produce 
“worst case” errors up to a maximum of 18mm3 necrotic core. However, as we have 
demonstrated in our volume analyses, subsequent over or under estimations can 
cancel each other out over the full lesion length. This may explain our relatively 
accurate error results of 6.7mm3 for necrotic core volume in variable segment 
lengths and 3.78mm3 for fixed length assessments.    
Importantly, a recent inter-catheter reproducibility study by Prasad et al in 2008 showed 
that in a subgroup of volumetric analyses, involving only 12 segments with a mean 
length of 11mm, the repeatability co-efficient for inter-catheter error produced large 
compositional differences of: Fibrous 13.89mm3; Fibrofatty 2.95mm3; Necrotic core 
10.46mm3 and Dense calcium 14.16mm3. These results and a warning in the 
discussion chapter of other papers [Hartman et al 2009; Huisman et al 2010; Rodriguez-
Granillo et al 2006] state that, between catheters and pullbacks, volumetric VH 
analysis produces high levels of measurement error. Despite these known issues, 
papers rarely document clearly (in mm3) the volumetric change that could be 
expected purely from total measurement error. They opt to only report percentages 
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or statistical analyses of paired differences, which may grossly under-estimate true 
errors in compositional volumes. The IBIS-2 trial [Serruys et al 2008] used data from 
the aforementioned Rodriguez-Granillo et al 2006 (single frame area analysis) to 
justify adequate reproducibility and variability of IVUS-VH volume analyses. In this 
study, change in necrotic core volume was used as a surrogate end-point to evaluate 
pharmacotherapy. The final absolute difference between placebo and darapladib 
treatment was a 5.2mm3 reduction in necrotic core volume. Unfortunately, this 
endpoint value lies within the inter-catheter reproducibility error for necrotic core in 
the study by Prasad et al (10.46mm3). This endpoint value of 5.2mm3 does appear to 
be measurable between operators on a single pullback, as it lies above our inter-
observer variability RCO of 3.78mm3. Moreover, the power calculation for the IBIS 
II trial was initially based upon primary endpoint palpography and HS-CRP data. 
239 patients were analysed by VH-IVUS but if a repeat power calculation is 
performed based on the data from the paper (Mean NC volumes around 22-26mm3 
with a standard deviation of 25), then 1200-1600 patients would have been required 
at a standard power (80%; α=0.5) to prove a real difference due to the drug alone. 
Clearly, these findings impact greatly on the validity of some serial studies in this 
field. Also, a very recent variability analysis by [Obaid et al 2011] has shown that in 
comparison to core-lab analysis there can be significant errors in judgement when 
identifying plaque sub-types (VH-TCFA etc) between operators. This further 
reduces the clinical utility of this tool and has implications for studies where 
different observers make judgements about plaque types. 
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4.6 Limitations 
This study was performed in a single centre, by two experienced operators, without 
the aid of an industry sponsored core-lab. Some of our analyses were performed by 
an operator purely on the S5i platform and in some cases these were compared with 
results from an operator on PC VIAS 3.0.394. Potential differences in the 
classification tree or software may therefore have influenced plaque components. 
However, it is hoped that there are not further variability errors to consider between 
software packages as well as operators, catheters and pullbacks.  
Studying high-risk ACS plaques introduces large variations between individual 
plaque components and therefore creates large SD values. This in turn affects the 
calculation of limits of agreement and the RCO. It may be that the inherent 
variability in these plaque types precludes them from future serial study or that the 
spread of this data makes the RCO less sensitive. Furthermore, our results can only 
be applied to this cohort of patients, examined by these operators and will therefore 
not be representative of future measurements made by other operators in non-ACS 
patients. Our aim has been to provide a cautionary guide to the potential for 
measurement error with this technique, even in experienced hands. This will 
hopefully forewarn future result interpretation by operators in a clinical setting. 
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4.7 Conclusions 
As in previous studies, there appears to be good agreement between IVUS-VH 
observers. However, when the standard deviation of the data is taken into account, 
this can occasionally represent large measurement error values and percentages. 
These findings could impact on the interpretation of previous studies and influence 
future studies using IVUS-VH measurements as endpoints. 
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CHAPTER V 
STUDY II 
The Creation and Validation of a Plaque Discrimination 
Score from the Anatomical and Histological Differences in 
Coronary Atherosclerosis. 
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5.1  Introduction 
Post-mortem pathological studies have shown that a “vulnerable” plaque is the 
dominant pathophysiological mechanism responsible for Acute Coronary 
Syndromes (ACS) [Falk et al 1995; Virmani et al 2000/2001]. One way to try and 
image these plaques in-vivo is by using histological “surrogates” created by 
intravascular ultrasound derived virtual histology (IVUS-VH) [Sawada et al 2008]. 
IVUS-VH has been validated in human pathological studies and atherectomy 
specimens [Nasu et al 2006]. The recent publication of the VIVA (Virtual Histology 
in Vulnerable Atherosclerosis) study [Calvert et al 2011]; has created a new interest in 
this potential role for IVUS-VH. This is because the study findings replicated the 
final results of the landmark PROSPECT (Providing Regional Observations to 
Study Predictors of Events in the Coronary Tree) study [Stone et al 2011]. Both 
studies concluded that important non-culprit lesion-specific characteristics are: Plaque 
Burden > 70%; VH-Thin Cap Fibroatheroma (VH-TCFA – a virtual surrogate for 
unstable plaque) and a Minimum Lumen Area (MLA) < 4mm2 
IVUS-VH is based upon the analysis of ultrasound backscatter as different plaque 
components produce a particular spectrum [Nasu K et al 2006; Van Herck et al 2009; 
Rodriguez-Granillo et al 2005]. The power, amplitude and frequency of the signal 
undergo de-convolution through a trained classification tree. This process 
transforms signals into four colour-coded pixels: fibrous (green); fibro-fatty tissue 
(light green); necrotic core (red) and dense calcium (white). This has been found to 
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correlate with histopathology and atherectomy specimens (predictive accuracy = 
87.1%, 87.1%, 88.3%, and 96.5% for fibrous, fibro-fatty, necrotic core, and dense 
calcium, respectively) [Nasu K et al 2006; Van Herck et al 2009; Rodriguez-Granillo et al 
2005].  
Numerous other studies have analysed ACS and stable culprit plaques with IVUS-VH 
[Garcia-Garcia et al 2006; Hong et al 2008; Qian et al 2009; Rodriguez-Granillo et al 2006; 
Surmely et al 2006; Nakamura et al 2006], however none have attempted to construct a 
discriminatory score based upon the specific anatomical and compositional changes 
seen in “active” culprit ACS plaques.  
5.2 Study Objectives 
We designed a prospective, observational study that would examine active culprit 
(AC) plaques from patients with an ACS presentation and stable culprit (SC) plaques 
from patients with clinically stable angina. The research aims were: 
1. To define the anatomical and histological differences between ACS and stable 
disease. 
2. To use these differences in a multiple logistic regression model that can 
assign a numerical value to each associated variable. 
3. To test the ability of this model to discriminate between plaque types in 
another independent cohort. 
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5.3  Study specific methods 
This was a single centre, prospective, observational cohort study that received ethical 
approval from the Cheshire National Health Service (NHS) ethics committee in the 
UK. Patients with a Troponin positive ACS diagnosed by a general Cardiologist were 
transferred urgently to our tertiary centre for PCI. These cases were screened and 
gave written informed consent to be involved in the study. The main exclusion 
criteria were: ST elevation MI; unsuitable anatomy for PCI; left main stem disease; 
chronic kidney disease; previous PCI in the target vessel and heavily calcified or 
visibly thrombotic vessels. Active Culprit plaques (AC) were defined as those 
meeting electrocardiographic (ECG) criteria for the ACS culprit vessel and where 
intervention was performed. Stable Culprit (SC) plaques were those requiring PCI 
for progressive symptoms and failure of medical therapy in an elective setting. All 
vessels were studied prior to any percutaneous revascularisation. Imaging of the 
vessel in each group was undertaken as described in our methodology section. The 
plaque composition and other analyses were performed by off-line IVUS-VH 
analysis by a single individual blinded to the patient details and mode of 
presentation. Single operator analysis of ACS plaques produces less measurement 
error as shown in our validation work, which has been previously published [Murray 
et al 2013].  
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5.3.1  Study specific statistics and power calculation 
To guide the initial sample size for this study, we used the hypothesis that the mean 
necrotic core volume will be variable between the two groups. Previous studies in 
ACS patients and our own variability study suggested that the mean would be 
around 35mm3 with a standard deviation (SD) for necrotic core +/- 28mm3. A 
sample size of 100 lesions was calculated. From this we expect 80% power to detect 
a 7mm3 difference in plaque components with an alpha of .05. This permitted the 
relative differences in the mean to be tested for statistical significance using a 
student’s t test. A p-value of <0.05 was considered significant. Continuous variables 
are expressed as means +/- standard error of the mean (SEM).  Statistically 
significant variables in culprit plaques were entered into a multivariate logistic 
regression analysis, with the forward stepwise technique [Hosmer et al 1989], to 
identify independent associations between plaque variables, with AC lesion 
phenotype being the dependant variable. Those variables that were strongest in the 
output from the regression each have a logistic regression co-efficient (Table 5.4). 
This co-efficient is then used to multiply each numerical value for that variable. (i.e 
0.675  X  NC/DC ratio =0.675 X 3.5=2.363).  The summation of the output for 
each associated variable then creates the overall “Liverpool Active Plaque Score” 
(LAPS). To assess model performance, receiver operating characteristics (ROC) data 
were examined. The area under the curve (AUC) and 95% confidence intervals (CI) 
were then estimated. A larger area under the ROC curve reflects better performance 
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of a discriminatory test. An AUC of greater than 0.5 suggests that the discriminatory 
power of the variable in question is superior to that of natural chance.   
5.3.2 Validation 
Following construction of the score, the diagnostic equation was taken to the 
Thoraxcentre, Rotterdam and applied to an independent cohort of 50 plaques taken 
from a previous three vessel IVUS-VH study [Garcia-Garcia et al 2006]. Each plaque 
score was initially calculated with the operator blinded to the independent lesion 
status, until the final ROC curve was calculated.  
5.3.3 Sample size considerations for logistic regression 
Sample size calculation for logistic regression is complex, but based on the work of 
Peduzzi et al from 1996 the following guideline for a minimum number of cases can 
be suggested: With p as the smallest of the proportions of negative or positive cases 
for the total population and k the number of covariates (the number of independent 
variables). The minimum number of cases to include is: N = 10 k / p. For our total 
population, p = 0.44 (68 stable (35 construction and 33 validation)/ 155 total lesions 
(105 construction and 50 validation) and k = 4 variables. Therefore from this 
equation: N =4x10/0.44; N=91 plaques. We have analysed a total of 155 plaques 
in our overall model and therefore should have statistical power. 
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5.4 Results 
Two hundred and thirty eight patients were approached after urgent ACS transfer 
and case note review.  Seventeen patients refused to participate and two hundred 
and twenty one were formally consented and enrolled before angiography. Eighty nine 
were excluded after angiography due to fulfilment of exclusion criteria. The majority 
of exclusions were due to the presence of surgical disease and/or heavy thrombus 
burden with reduced TIMI flow in the culprit vessel. One hundred and thirty two 
lesions were suitable for IVUS. However, in 19 cases the IVUS failed to cross or was 
abandoned and in 8 cases the IVUS pullback was not sufficient for analysis or there 
were media problems preventing full analysis. Therefore, a total of one hundred and 
five lesions were analysed; seventy culprit lesions in ACS patients and a further thirty 
five culprit lesions from stable angina patients undergoing PCI.  
The patient baseline characteristics are displayed in table 5.1 Of note, there was a 
statistically significant difference in the vessel interrogated between plaque types with 
more left anterior descending or diagonal (LAD/D1) arteries imaged in the stable 
cohort and a more even distribution in the ACS group: LAD/D1 (41%); Circumflex 
(25%); Right Coronary (34%). There were no significant differences in conventional 
risk factors for coronary artery disease; however the ACS cohort were more likely to 
have had a previous myocardial infarction (16% Vs. 7% p=0.02). 
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Table 5.1 Patient baseline characteristics 
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A comprehensive observational assessment of plaque anatomy and virtual histology 
is presented in tables 5.2 and 5.3. Total plaque length is statistically greater in the 
ACS culprit group, combined with a greater total plaque volume and burden, which 
heavily influences the relative volume calculations for individual VH plaque 
components displayed in table 5.3. Plaque volumes are therefore corrected for 
length by displaying the measured percentage contribution of each plaque type. 
Subsequently, the only VH variable that shows a statistical difference between 
groups is dense calcium plaque, being increased within stable plaques. Creating a 
ratio between important plaque types also corrects for volume differences and we 
have shown that there is a statistical difference in the Necrotic Core volume/Dense 
Calcium volume (NC/DC) ratio between ACS culprit and Stable plaques.  
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Table 5.2 Plaque anatomical analysis (grayscale IVUS). 
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Table 5.3 – Plaque Histological analysis (Virtual Histology) 
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Figure 5.1 above, shows the angiographic appearance of a culprit ACS plaque 
(Frame A) with VH frames shown at both the site of maximum necrotic core 
(Frame B) and the minimum lumen area (MLA) (Frame C). This highlights the 
eccentric nature and positively remodelled disease typically seen in ACS culprit 
plaques.  
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In comparison Figure 5.2 (below) shows the angiographic image of a stable culprit 
coronary lesion in the proximal RCA. The minimum lumen area (Frame B) shows a 
significant amount of circumferential calcification and relative negative remodelling. 
Frame C shows the maximum necrotic core frame confirming disease that is less 
eccentric and mixed in composition.  
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Figure 5.3 (below) displays the ROC analysis for each plaque variable that was 
statistically significant in the construction logistic regression. Interestingly this shows 
the relative importance of the remodelling index at the minimum lumen area 
(RI@MLA) and the necrotic core to dense calcium ratio (NC/DC) in comparison to 
minimum lumen area <4mm2 (MLA<4) and VH-TCFA.  
 
Figure 5.3: ROC curve analyses for each statistically significant variable 
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Table 5.4 (below) shows the output from the regression analysis and the relevant 
calculated co-efficients that make up the score. 
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 Figure 5.4 (below) displays the regression equation that calculates the Liverpool 
Active Plaque Score (LAPS) and the ROC curve showing the strong discriminatory 
power for an active plaque phenotype (in the construction cohort).   
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Figure 5.5 (below) is the ROC curve derived when the LAPS was applied to an 
independent cohort of plaques analysed at the Thoraxcentre, Rotterdam. As 
expected, the discriminatory ability of the score is reduced. However, the AUC value 
of 0.71 confirms that the score maintains some predictive discriminatory ability for 
active (AC) plaque phenotypes.  
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Figure 5.6 (below) is a box and whisker plot showing the differences and full 
descriptive distribution of the LAPS between AC and SC presentations in 155 
plaques.  
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Figure 5.7 (below) is a visual illustration of the results from the application of the 
LAPS, where a score >6 is more typical of an active phenotype and a score <6 is 
more likely to represent a stable presentation. This is shown to emphasise how the 
score could be applied to stratify coronary artery plaques. 
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5.5 Discussion  
The in-vivo assessment of high-risk atherosclerotic plaque characteristics may help 
improve our understanding and accuracy to reliably identify vulnerable plaques in 
the future. We have analysed the differences between the anatomical and virtual 
histological features in culprit coronary plaques from both unstable and stable 
presentations. Using logistic regression we have both determined the important 
features found in plaques responsible for ACS events and assigned a numerical value 
to these, allowing the calculation of a summative score with discriminatory power. 
Although many of the features within our score have been previously discussed in 
the IVUS-VH literature [Garcia-Garcia et al 2006; Hong et al 2008; Qian et al 2009; 
Rodriguez-Granillo et al 2006; Surmely et al 2006; Nakamura et al 2006] and found to be 
more prevalent in culprit plaques, this is the first attempt at modelling a plaque score 
from IVUS and VH data. The aim of this was to generate a concept that could be 
taken forward in larger trials and applied to future lesions and studies, possibly with 
more advanced imaging techniques such as: Coronary CT; Optical Coherence 
Tomography (OCT) and Near Infra-Red Spectroscopy (NIRS). Identifying the high 
risk features of plaques that have been shown to correlate with future MACE in 
previous studies [Calvert et al 2011; Stone et al 2011] is of paramount importance from 
both a preventative and an interventional point of view. Moreover, creating a 
reproducible score could allow both proper validation and invasive assessment of 
pharmacological agents aiming to modify vulnerable plaque features [Rodriguez-
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Granillo et al 2005]. It may also be conceivable that in the future a “master” plaque 
risk score could be produced following further studies. The overall aim of this 
concept would be to guide cardiologists towards “staging” plaques where the risk of 
a future event occurring may be greater than the risk of treatment with a particular 
drug or device, such as:  high dose statins, PCSK9 inhibition, darapladib or 
bioabsorbable vascular scaffolds (BVS) [Wykrzykowska et al 2012]. The variables that 
have formed our score and are associated with culprit ACS plaque presentations 
include similar findings from both VIVA and PROSPECT [Calvert et al ; Stone et al 
2011] with MLA and VH-TCFA found again to be important. However, given our 
study focussed on culprit plaque morphologies, we add to this the remodelling index 
at the MLA (RI@MLA) and the necrotic core/dense calcium ratio (NC/DC). Both 
of these findings have previously been found to indicate an unstable lesion 
phenotype [Garcia-Garcia et al 2006; Pasterkamp et al 1998; Missel et al 2008] and even 
been linked to sudden death [Missel, Mintz et al 2008].  
Our study examined the most pathologically important part of the vessel, 
responsible for the ACS event, before PCI. This has allowed us to observe vital 
information about residual plaque characteristics in a contemporary setting. The 
PROSPECT trial examined the VH appearance of non-culprit, angiographically 
insignificant, lesions that eventually caused re-admission to hospital with unstable 
angina. The actual myocardial infarction (MI) rate in the follow-up cohort was low at 
1%. This is a direct reflection of the study protocol, which required all significant 
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angiographic lesions to undergo PCI before IVUS-VH analysis. Therefore, the results 
of PROSPECT do not inform us about the composition of culprit plaques 
implicated in a confirmed MI presentation. The VIVA study acquired three vessel 
IVUS in both unstable and stable atherosclerosis before PCI, but again the rate of MI 
during follow up was low, with end points being driven by revascularisation not MI. 
Although the total number of plaques analysed in this study is small compared to 
PROSPECT and VIVA, the number imaged in the context of a confirmed MACE 
event (n=70 (construction) + n=17 (validation) = 87) is greater than in PROSPECT 
(n=55) and VIVA (n=19) combined. 
The inclusion of the NC/DC ratio within the score does merit some discussion as 
previously in the literature, the impact of dense calcium measurement on necrotic 
core coding on VH has been investigated [Murray et al 2009; Sales et al 2010]. We 
found that stable culprit (SC) plaques have statistically higher values for dense 
calcium but not for necrotic core. It has previously been shown on some analyses 
[Kubo et al 2010] that dense calcium in VH analysis begets the identification of 
necrotic core behind the calcium signal. Although this is certainly observed in some 
situations, it does not seem to have statistically influenced our overall volume 
measurements. Moreover, calcium in a spotty distribution within relatively larger 
necrotic cores (i.e. a high NC/DC level) appears to be a more important phenotype 
and this has previously been observed, pathologically, in sudden coronary death 
victims [Virmani et al 2000]. 
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 The NC/DC ratio in our cohort proved to be a significant independent predictor of 
a culprit lesion phenotype alone with an individual construction AUC of 0.78. 
The influence of positive remodelling at the site of the MLA was very strong in our 
cohort (individual AUC – 0.83). This may be explained by the eccentric plaque 
burden seen in culprit ACS plaques or that extensively remodelled plaques are 
biologically active and have an increased tendency to weaken at the luminal surface, 
when the fibrous cap thins or an unknown Glagovian expansive limit is reached 
[Garcia-Garcia et al 2006; Pasterkamp et al 1998; Nakamura et al 2001; Schoenhagen et al 
2000; Kaple et al 2009; Rodriguez-Granillo et al 2006; Fuji et al 2005; Kroner et al 2011 and 
Missel et al 2008].  The presence of more negatively remodelled plaques with greater 
dense calcium, in stable angina, may be explained by plaque contraction as necrotic 
core and macrophages “burn-out” and undergo calcification.  
Further interesting insights from our data relate to the influence of the vulnerable 
plaque surrogate VH-TCFA in plaque diagnostics. This has previous been linked 
with future MACE events [Calvert et al 2011; Stone et al 2011]. In our cohort, VH-
TCFA presence within the interrogated plaque disease was greater in the culprit ACS 
plaques compared to stable angina. However, on a discriminatory level, VH-TCFA 
has an individual AUC of 0.57, suggesting it has modest diagnostic ability. The 
limitations of the VH-TCFA concept have been described elsewhere before 
[Rodriguez-Granillo et al 2005; Garcia-Garcia  et al 2009; Kubo et al 2010]. IVUS-VH 
cannot define true thin-caps, due to the resolution of a 20MHZ IVUS catheter being 
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in the order of 150µm.  Also, VH-TCFA lesions are found within culprit stable 
angina lesions and this therefore weakens their discriminatory power. Moreover, it 
has been shown that these lesions are dynamic and fleeting in nature with around 
75% “healing” over a year [Kubo et al 2010], this weakens their overall influence on 
culprit ACS lesion diagnosis, In addition, a recent study from the VIVA group has 
shown unacceptable variability in VH-TCFA recognition and the process of 
individually naming plaque sub-types (such as Thick fibrous Cap Atheroma 
(ThCFA) etc) [Obaid et al 2012]. This leads us critically to the concept generated by 
this investigation. It is clear that our work provides a basic “pilot” idea in this field, 
that could be taken forward in future investigations, hopefully with additional 
information gained from  other imaging tools such as OCT (which can define true 
thin caps <65 µm) and NIRS (highly sensitive for lipid core). More importantly, 
most of the plaque variables we have found in this investigation can now be 
measured by non-invasive cardiac computerised tomography. Therefore, there may 
be a role for this theory in the preventative screening of asymptomatic plaques 
found in individuals with familial hazard or abnormal conventional risk factors. 
5.5 Limitations 
This is a single centre, observational study with the inherent limitations of this 
design. Although efforts were made to blind the analysing operator to the 
presentation type, it can occasionally be clear when a plaque is a culprit, due to the 
presence of residual thrombus and plaque rupture. This is a potential source of bias. 
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The analysis of MLA<4cm2, RI>1.05 and VH-TCFA with logistic regression 
required these datasets to be converted to binary responses, which may not be 
representative of what is reported in the real world. In this study we imaged the full 
volume data from culprit plaques a few days after an event had occurred within the 
plaque. Although this is as close as we can realistically come to phenotyping event 
associated unstable plaques, we still cannot say with certainty what the pinpoint 
anatomy and histology was at the point of rupture/erosion. Analysis of high-risk 
ACS culprit plaques required interrogation of IVUS images containing rupture 
cavities and thrombus at varying stages of progression and therefore we followed 
previously published guidance by including thrombus in the plaque analysis where 
possible [Garcia-Garcia et al 2009]. This is notoriously difficult and previous studies 
have shown a difference between independent IVUS-VH measurements and 
measurements performed in a core-lab facility [Obaid et al 2012; Huisman et al 
2010/2012]. However, we have published our magnitude of measurement variability 
in high risk ACS plaques, following a previous in-depth study [Murray et al 2013] and 
also have three previous peer-reviewed publications involving the identification of 
thrombus on IVUS [Murray et al 2009/2010]. 
 
 
 
[162] 
 
5.6 Conclusion 
We have found four features on IVUS and VH that can predict and discriminate 
active ACS culprit lesion phenotypes from those that are clinically stable. 
Subsequently, we have constructed and validated the Liverpool Active Plaque Score 
based upon these features. Although the main outcome of this study is concept 
generating, it is hoped that in the future a similar score may allow the prospective 
identification, staging and aggressive treatment of active coronary plaques to prevent 
major adverse cardiac events.   
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CHAPTER VI 
STUDY III 
Observable patterns of site-specific plaque morphologies 
by IVUS-VH: The relationship between maximum 
necrotic core site and minimum lumen area with 
implications for the identification of vulnerable plaque 
phenotypes. 
 
 
 
 
 
 
 
[164] 
 
6.1 Introduction 
Numerous other studies have analysed atherosclerosis with IVUS-VH [Calvert et al 
2011; Stone et al 2011; Garcia-Garcia et al 2006; Hong et al 2007/2008; Qian et al 2009; 
Surmely et al 2006; Nakamura et al 2009]. The main focus of these studies has been on 
conventional parameters and outputs from a standard Virtual Histology (VH) 
analysis. However, no study has focussed on remodelling index and the relationship 
that exists between necrosis and calcification. We have analysed this to try and find 
patterns or “blueprints” that might explain the progression of individual plaque 
phenotypes from stable disease to those seen in acute coronary syndromes. This may 
involve differential plaque growth, eccentricity, distance between minimum lumen 
area and a migrating or fluctuating presence of necrotic core. 
Moreover, the process of plaque calcification is incompletely understood and 
documentation or measurements of calcification patterns are difficult. It is not 
completely clear what role progressive calcification plays in plaque instability [Joshi et 
al 2014; Ehara et al 2004; Fujii et al 2005]. Recently, a novel nuclear tracer of active 
calcification (18F-NaF) has been found to highlight both ruptured and high risk 
plaques using Positron Emission Computed Tomography (PET CT) [Joshi et al 2014]. 
The Virtual Histology analysis of the tracer positive plaques appeared to show more 
evidence of positive remodelling and micro-calcification.  
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We therefore examined, in an observational study, culprit plaques implicated in a 
troponin positive acute coronary syndrome (ACS) and stable plaques responsible for 
symptomatic angina pectoris. The research aims were: 
1. To define site-specific differences in atherosclerosis between ACS and 
stable disease. 
2. To identify differences in remodelling and calcification patterns at:  
a) Minimum Lumen Area (MLA) 
                b) Site of maximum necrotic core content (Max NC).  
3. To create novel markers of vulnerability and/or plaque “blueprints” from 
frequent patterns or observable recurrent characteristics. 
 
6.2 Methods 
These have been described within the main methodology chapter and within the 
previous chapter. 
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6.2.1 Study specific methods of detailed plaque analysis using VH. 
From the previously published chapter, looking at entire plaques and the volume of 
plaque components, we have shown that certain measurable factors can help 
distinguish “active” plaques present in acute coronary syndromes [Murray et al 2014]. 
In particular, minimum lumen area (MLA), plaque burden (PB), necrotic core to 
dense calcium ratio (NC/DC) and remodelling index (RI) were the most important 
factors in a multivariate prediction model.  For this current work we have applied 
these findings to site-specific points within plaques (MLA and MAX NC) to explore 
in more detail the relationship between remodelling, necrosis and calcification. 
Necrotic Core to Dense Calcium ratio (NC/DC) was therefore calculated for 
individual plaque areas. However, we also calculated (NC+DC/DC) area in an 
attempt to quantify mathematically a surrogate for the amount of interfacial 
connection between NC and DC. We have named this measurement the Calcified 
Interface Area (CIA). Also, DC/NC area X 100 was calculated as a representation of 
the calcification that has developed respective to the necrotic core; this has been 
given the term Plaque Calcification Equipoise (PCE). A single previous study has 
defined micro-calcification as being evidence of “spotty” calcification on three 
frames or more with no evidence of acoustic shadowing behind the calcium [Joshi et 
al 2014]. However, our view was that calculating the PCE and CIA provides more 
continuous and reproducible variables that can better define the relationships within 
calcifying necrosis. The remodelling index was defined as the ratio between the 
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external elastic membrane cross-sectional area of the specific site (MAX NC or 
MLA) and the average of the proximal and distal reference regions in the same 
vessel. The maximum necrotic core frame (MAX NC) was defined as the frame with 
the highest percentage of necrotic core on a single frame.  
6.2.2 Study specific statistics and power calculation 
To ensure significant power was available for this sub-study, a retrospective post-hoc 
analysis was made using the results achieved for calcium interface area (CIA). The 
mean for one group was 3.58 (±2.26) and for the other 5.38 (±2.71). Therefore, for 
an Alpha of 0.05 over 105 plaque sites, the power to detect a statistical difference 
was calculated at 94.8%. Continuous variables are expressed as means +/- standard 
deviation (SD).                                                                                            
On comparing plaque sites a Student’s t-test was used when the data was normally 
distributed, however if variances were unequal or a two sided F test was significant a 
Mann-Whitney U test was performed to ensure statistical significant was met for 
median values. A P value of ˂0.05 was taken as indicating a statistically significant 
result. Receiver operator characteristics were used again to test the discriminatory 
ability of certain plaque variables, this was done with the binary classification: 1= 
(CP ACS culprit/Troponin +); 0 = (SP Stable Plaque). Plaque variables that have 
shown statistical differences between these groups were also explored by simple 
linear regression to determine any correlation. 
[168] 
 
6.3 Results 
Two hundred and thirty eight patients were approached after urgent ACS transfer 
and case note review.  Seventeen patients refused to participate and two hundred 
and twenty one were formally consented and enrolled before angiography. Eighty nine 
were excluded after angiography due to fulfilment of exclusion criteria. The majority 
of exclusions were due to the presence of surgical disease and/or heavy thrombus 
burden with reduced TIMI flow in the culprit vessel. One hundred and thirty two 
lesions were suitable for IVUS. However, in 19 cases the IVUS failed to cross or was 
abandoned and in 8 cases the IVUS pullback was not sufficient for analysis or there 
were media problems preventing full analysis. Therefore, a total of one hundred and 
five lesions were analysed; seventy culprit lesions in ACS patients and a further thirty 
five culprit lesions from stable angina patients undergoing PCI.  
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The patient characteristics are below in Table 6.1  
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6.3.1 Site comparisons within the same plaque (CP or SP) 
Following the analysis of 2 separate sites (MAX NC and MLA) in each individual 
plaque (n =70 x 2 CP and n=35 x 2 SP); a total of n=210 separate plaque sites were 
analysed and measured.  In general, more left anterior descending arteries were 
examined in the stable group with more right coronary and circumflex arteries being 
involved in the ACS group. More ACS patients had suffered a previous myocardial 
event. An overview of the focussed IVUS and VH comparisons for each plaque type 
and site is present in Tables 6.2-6.5. 
Table 6.2 – Site Comparisons within Stable Plaques (SP) n=70 
 
Within each particular type of plaque (CP/SP) there are statistically significant 
differences at specific points within the plaque. Table 6.2 shows that in stable 
plaques (SP) n=70, despite the obvious differences in lumen area (MAX NC 6.04 
mm (±2.97) Vs MLA 3.61mm (±1.34)), there remains a substantial plaque burden at 
Variables Plaque at Maximum Necrotic 
Core Site (MAX NC) 
Plaque at Minimum 
lumen area Site (MLA) 
P-Value 
Lumen Area 6.04 (±2.97) 3.61 (±1.34) <0.001 
Plaque Burden % 59% 68% 0.004 
NC/DC 2.57 (±2.25) 2.74 (±2.82) 0.79 (NS) 
Remodelling Index 1.1    (±0.17) 0.95 (±0.14) <0.001 
Calcium Interface Area (CIA) 3.58 (±2.26) 2.36 (±1.07) 0.005 
Plaque Calcification Equipoise 
(PCE) % 
54% 56% 0.68 (NS) 
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the MAX NC site (59%). As expected, plaque burden is greater at both the MLA 
and CP sites. This appears to be accommodated by a greater amount of positive 
remodelling (1.1 (±0.17) Vs 0.95 (±0.14)) sparing luminal integrity. The MLA point 
of a stable plaque is more likely to display negative remodelling (RI 0.95 (±0.14)). 
Also, each of these individual plaque sites appears to have similar values for NC/DC 
ratios (2.57 (±2.25) Vs 2.74 (±2.82)). However, the pattern of this differs at the 
MAX NC site, having a greater calcified interface area (CIA) (MAX NC 3.58 (±2.26) 
Vs MLA 2.36 (±1.07).  
Table 6.3 – Site Comparisons within culprit ACS plaques (CP) n=140 
 
Table 6.3 shows the results for culprit ACS plaques (CP) n=140, and interestingly a 
similar pattern emerges. However, these plaques appear to have less calcification and 
greater amounts of positive remodelling both at the MLA and MAX NC site. 
Variables Plaque at Maximum Necrotic 
Core Site (MAX NC) 
Plaque at Minimum 
lumen area Site (MLA) 
P-Value 
Lumen Area 5.93 (±2.67) 2.98 (±1.27) <0.001 
Plaque Burden % 66% 79% <0.001 
NC/DC 4.38 (±2.72) 3.46 (±3.48) 0.08 (NS) 
Remodelling Index 1.34 (±0.18) 1.20 (±0.13) <0.001 
Calcium Interface Area (CIA) 5.38 (±2.72) 4.33 (±3.61) 0.001 
Plaque Calcification Equipoise 
(PCE) % 
30% 43% 0.004 
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Moreover, the MAX NC site within a culprit plaque has the greatest amount of 
positive remodelling (RI 1.20 (±0.13) Vs 1.34 (±0.18) P<0.001). 
6.3.2   Site comparisons between CP and SP (n=210)  
Table 6.4 – MAX NC site comparisons between stable and ACS plaques. 
 
On direct comparison between CP and SP at these specific points in the plaque 
(Table 6.4 and 6.5) we can again observe statistical differences. With regard to the 
MAX NC site; there is generally more necrosis than calcification. This is shown by 
PCE values less than 50% and subsequently higher calcified interface areas (smaller 
amounts of calcification) with greater amounts of positive remodelling. At the MLA 
in stable plaques, there appears to be an increasing amount of calcification 
(PCE>50% and lower CIA <3) coupled with more negative remodelling (RI < 1). 
This is the opposite of what is occurring in ACS culprit plaques (PCE <50%, CIA >  
4 and RI >1).  
Variables Plaque at Maximum Necrotic 
Core Site (MAX NC) - STABLE 
Plaque at Maximum Necrotic 
Core Site (MAX NC) - ACS 
P-Value 
Lumen Area 
 
6.04 (±2.97) 5.93 (±2.67) 0.85 
Plaque Burden % 
 
59% 66% 0.012 
NC/DC 
 
2.57 (±2.25) 4.38 (±2.72) <0.001 
Remodelling Index 
 
1.1    (±0.17) 1.34 (±0.18) <0.001 
Calcium Interface 
Area (CIA) 
3.58 (±2.26) 5.38 (±2.72) =0.001 
Plaque Calcification 
Equipoise (PCE) % 
54% 30% <0.001 
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Table 6.5 – MLA comparisons between Stable and ACS plaques (n=210) 
 
Figure 6.1 – Virtual Histology evolution of plaque from primitive necrosis and spotty 
calcium through to calcium arcs. Each stage shows values for NC/DC ratio, PCE (plaque 
calcification equipoise) and CIA (calcified interface area). 
 
Variables Plaque at Minimum Lumen 
Area Site (MLA) - STABLE 
Plaque at Minimum Lumen 
Area Site (MLA) - ACS 
P-Value 
Lumen Area 3.61 (±1.34) 2.98 (±1.27) 0.021 
Plaque Burden % 68% 79% <0.001 
NC/DC 2.74 (±2.82) 3.46 (±3.48) 0.26 (NS) 
Remodelling Index 0.95 (±0.14) 1.20 (±0.13) <0.001 
Calcium Interface 
Area (CIA) 
2.36 (±1.07) 4.33 (±3.61) <0.001 
Plaque Calcification 
Equipoise (PCE) % 
56% 43% 0.068 
[174] 
 
These results, demonstrated visually in figure 6.1, shed some light on the intricate 
pathological changes that are occurring in plaques at different stages of 
atherosclerosis. Graphical explanations of the results (as an aid to comprehension) 
are displayed in Figures 6.2, 6.3 and 6.4. 
 
FIGURE 6.2: Histogram showing significant differences in remodelling index 
and calcified interface area at the minimum lumen area (MLA) in both ACS 
and stable plaques. 
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Figure 6.3: Histogram showing significant differences in remodelling index 
and calcified interface area at the Maximum Necrotic Core (MAX NC) site in 
both ACS and Stable plaques. 
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Figure 6.4: Histogram showing mean PCE across the major plaque sites in both 
ACS and Stable plaques. This displays the change in percentage calcification between 
different clinical presentations. 
 
[177] 
 
These site-specific statistical differences have been explored using ROC analysis to 
look for discriminatory ability. This is shown in figures 5 and 6. Although the area 
under the curve (AUC) and sensitivity/specificity vary somewhat (0.86-0.65 and 
97%-51%) the best cut-off values to determine“culprit plaque-like” morphologies 
are: RI @ MLA>1.12; RI @ MAX NC>1.22; PCE @ MLA<47.1%; PCE @MAX 
NC<47.3%; CIA @ MLA>2.6; CIA @ MAX NC>3.1. 
Analysis of the data, to look for correlations between remodelling index and patterns 
of atherosclerosis/calcification, shows the following: 
1. There does not appear to be a statistically significant direct correlation 
between remodelling index and PCE. However, there is a weak negative trend 
(p<0.09) in stable plaques; as plaque calcification increases the remodelling 
index can decrease. (Figure 6.7) 
2. Although not significant (p=0.07), there is a trend in stable plaques towards a 
positive correlation between CIA and remodelling index (Figure 6.7).  
3. There is a statistically significant negative correlation between Calcified 
Interface Area (CIA) and Plaque Calcification Equipoise (PCE) in 3 out of 4 
measurements in both CP and SP, suggesting that as plaque calcification 
increases the interface area decreases. This relationship is shown in Figure 6.8 
and 6.9. 
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Figure 6.6: ROC curve for CIA showing reasonable discriminatory ability for ACS 
plaques using this measurement obtained both at MLA and MAX NC sites. 
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Figure 6.7: Scatter plots of linear regression looking for a correlation between 
Remodelling Index and both PCE and CIA. Weak trends are seen at stable 
plaque MLA. 
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6.8: Scatter plots of linear regression showing a confirmed correlation 
between CIA and PCE in both stable and ACS plaques. Stable lesions at the 
MLA site (Panel B) do not have such a smooth curvilinear relationship due to 
the fact that these sites are the most heavily calcified already and therefore 
have a low baseline CIA (Y-axis) compared to other sites.  
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6.4  Discussion 
New indices and to assess plaque vulnerability and suggest possible instability, before a 
fatal event, are urgently called for. We have presented a series of novel observational 
virtual histology IVUS findings gathered from the analysis of 210 plaque sites across 
the spectrum of stable and unstable coronary disease. VH characterisation reveals (in 
ACS culprit plaques) the striking feature of positive remodelling and primitive 
“spotty” calcification within the necrotic core (CIA↑ PCE↓). We have also shown 
via our calculations that stable phenotypes tend to have a greater extent of 
calcification as measured by the PCE (>47%). This cut off value (close to 50% 
calcification of necrotic core) is the “equipoise point” where a plaque is in calcific 
transition from a potentially unstable (spotty-type) to a more organised stable form, 
hence the term PCE. Also, through calculating the CIA, we have shown that 
potentially different patterns of calcification can exist despite similar values for NC, 
DC, NC/DC ratio or PCE. This has been evident when comparing MAX NC and 
MLA sites within a stable plaque and also when comparing the MLA point of a 
culprit plaque (CIA <3) with that of a stable plaque (CIA >3). Our data also suggests 
a correlation between PCE and CIA (PCE↑, CIA↓). As a reference, NC/DC ratio 
was only statistically different when comparing the MAX NC site between SP and 
CP, whereas PCE, CIA and remodelling index were statistically different at five out 
of six sites between SP and CP.  
Previously, the NC/DC ratio on VH analyses has been shown to correlate with risk 
factors for sudden cardiac death and high risk ACS presentations                      
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[Missel and Mintz et al 2008]. With regard to the process and role of plaque 
calcification, it is interesting to discuss this based on a “friend or foe” analogy.                                                                                                                                                                                                                                                                                                                                                                                                                                                         
Coronary calcium correlates with plaque burden [Missel et al 2008; Maehara et al 2002] 
but its effect on plaque instability is less evident. Beckman et al in 2001 demonstrated 
that the maximal arc of calcium decreased progressively from patients with stable 
angina (91±10°), to those with unstable angina (59±8°) and finally to those with 
myocardial infarction (49±11°, p =0.014). Ehara et al in 2004 reported that the 
average number of calcium deposits (within an arc of 90°) decreased progressively in 
patients with acute myocardial infarction, compared with unstable angina and those 
with stable angina. Calcium deposits were also longer in patients with stable angina. 
Fujii et al in 2005 showed that ruptured plaques also had quantitatively less calcium 
but a larger number of small calcium deposits when compared with non-ruptured 
plaques. It appears that primitive spots of calcification within the necrotic core may 
be our foe but as calcification progresses there is a point where it may have a 
stabilising effect. The individual nuances behind these previous findings can again be 
explained by our calculations of CIA and PCE (figure 6.1 and 6.9).  As the PCE 
increases towards 50% and the CIA falls below 4, a certain amount of “plaque 
contraction” appears to occur as the biologically active necrotic core is “consumed” 
by calcification.  The vessel remodelling in stable plaques with these features is more 
negative and a trend towards this has been shown on linear regression (figure 6.8). 
This is in keeping with multiple previous analyses highlighting that positive 
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remodelling is more prevalent in acute coronary syndrome plaques [Virmani et al 
2000;  Garcia-Garcia et al 2006; Hong et al 2007; Joshi et al 2014; Murray et al 2014]. 
 
Figure 6.9: Graphical representation of the “bell curve” relationship between 
increasing calcium within a lesion and the interfacial area between calcium and 
necrosis as calcium coalesces. 
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It could be suggested that the development of primitive or nascent calcification, 
starting as microscopic “spotty” islands in a sea of active necrotic core, is the process 
highlighted by 18F-NaF on PET CT [Joshi et al 2013] and therefore we have suggested 
a theory that could explain the increased risk of these plaques to rupture and cause 
events.  
Previous biomechanical studies suggest that at the interface between a solid impurity 
(calcium) and a softer compound (necrosis), the large divergence in material 
resistance creates local strain concentrations at the poles of the impurity [Hoshino et al 
2009; Vengrenyuk et al 2006; Bluestein et al 2008; Cilla et al 2013; Huang et al 2001; 
Maldonado et al 2012; Knesi et al 2007]. Theoretically, should the stress placed on these 
areas change suddenly, via known plaque rupture triggers, such as increases in blood 
pressure or localised vasomotor function (sympathetic stimulation), then subsequent 
tissue de-bonding could occur, separating these tissues and precipitating plaque 
fissuring/rupture. We have suggested that these points (when seen at the luminal 
surface/cap) could be called “Stress Interface Mismatch Points (SIMPS)” See Figure 
6.10.  
The prevalence of these sites within a plaque is difficult to define accurately with 
IVUS-VH. However, we have attempted to infer the presence of more primitive 
calcification through the calculation of our two novel markers (PCE and CIA). As 
previously discussed, as a plaque “heals” and stabilises (PCE ↑ and CIA ↓) this 
would decrease the prevalence of stress interface mismatch points (SIMPs) between 
the calcium speckles, as the intermediary necrotic core is replaced by calcium fusing. 
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A future study may be warranted to explore this theory in more detail with optical 
coherence tomography analysis. This would more accurately determine the 
prevalence of point vulnerability where lipid or necrosis meets calcification at thin 
fibrous caps.  In further support of our observational theory for plaque vulnerability, 
biomechanical analyses using finite element analysis (FEA) models appear to 
confirm that micro-calcifications can alter the maximal principal stress by up to 32% 
[Cilla et al 2013].  In this paper, the fibrous cap thickness, micro-calcification ratio, 
eccentricity and angle appear to be the key morphological parameters that play a role 
in the overall rupture risk of the plaque. 3D FEA has also showed that local stress 
concentrations could be increased five-fold in the tissue space between micro-
calcifications, especially when they were in close proximity to each other [Maldonado 
et al 2012; Knesl et al 2007].  
According to the science of linear elastic fracture mechanics, if a system consisting 
of two edge-bonded wedges of different materials is considered, a stress-singularity 
occurs at the vertex of the bi-material interface [Knesl et al 2007]. The existence of 
these “stress-singularities” means that micro-failure processes can occur at the 
interfaces, leading to crack initiation and propagation (described in figure 6.10). 
Further circumferential stress on the plaque could be generated by segmental 
coronary endothelial dysfunction, creating imbalances in vasoconstriction and 
vasodilatation. In addition, circadian pulses in blood pressure or increases in shear 
stress along the shear points of these weak spots, could be a trigger for the tissue de-
bonding and rupture at these sites. Overall, our stress interface mismatch point 
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theory could explain the importance of plaque calcification patterns in the 
identification of vulnerable plaques and why “spotty” calcification is associated with 
increased plaque risk. This has been shown to increase the risk of ACS occurring in a 
group followed up after coronary artery CT [Motoyama et al 2009].   
 
 
 
Figure 6.10: Virtual Histology explanation of the Stress Interface Mismatch 
Point (SIMPS) theory of plaque instability, trigger and rupture based upon 
evidence from biomechanics and finite element analysis. 
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6.5  Limitations 
This is a single centre, observational study with the inherent limitations of this 
design. Our theory is observational and experimental in nature and is built upon the 
detailed scrutiny of both the IVUS and VH images at each individual plaque frame. 
Although efforts were made to blind the analysing operator to the presentation type, 
it is occasionally  clear when a plaque is a culprit, due to the presence of thrombus 
and plaque rupture. This is a potential source of bias. Analysis of high-risk ACS 
culprit plaques required interrogation of IVUS images containing rupture cavities 
and thrombus at varying stages of progression and therefore we followed previously 
published guidance by including thrombus (when seen) in the plaque analysis where 
possible [Garcia-Garcia et al 2009]. This can be difficult and previous studies have 
shown a difference between independent IVUS-VH measurements and 
measurements performed in a core-lab facility [Obaid et al 2012; Huisman et al 2010]. 
However, we have published our magnitude of measurement variability in high risk 
ACS plaques, following a previous in-depth study [Murray et al 2012]. The inclusion 
of ratio scores and percentages where DC and NC are involved  does merit some 
discussion as previously in the literature the impact of dense calcium measurement 
on necrotic core coding from VH has been investigated [Murray et al 2009; Sales et al 
2010]. It has previously been shown on some of these analyses that dense calcium in 
VH analysis begets the identification of necrotic core behind the calcium signal. 
Although this is certainly observed in some situations, it previously did not 
statistically influence our previous volume measurements [Murray et al 2014].  
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Even if larger arcs of calcium are present this would still lead to a lower NC/DC or 
CIA compared to a plaque with small speckles of calcium and a large positively 
remodelled necrotic core. We are aware that VH is a crude surrogate or “window” to 
the true plaque histopathology (as the algorithm was built around a single 
pathologists interpretation of “calcifying necrosis”). However,  in support of VH, a 
recent analysis by the Cambridge group comparing VH to conventional histology 
[Obaid et al 2013] revealed that there still appears to be reasonably good diagnostic 
accuracy for calcified plaque components (92%). Also VH-TCFA was able to detect 
histological TCFAs with a diagnostic accuracy of between 74-82%.  
6.6 Conclusion 
Virtual Histology IVUS produces reasonable surrogate measurements for the true 
histological composition of coronary artery plaques. From this we have found 
different patterns in site-specific plaque morphologies, both within an individual 
culprit plaque and between culprit plaques with different clinical presentations. 
Determining the stage of calcifying necrosis, along with the remodelling index can 
discriminate between stable and ACS related plaques. These findings could be 
applied in the future to help detect and stage plaques that have features of a 
vulnerable phenotype. 
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CHAPTER VII 
STUDY IV 
 The Intravascular Relationship of Proximal Unstable Plaque 
Components to the Minimum Lumen Area Stenosis: 
Implications for Coronary Stent Implantation. 
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7.1 Introduction 
Recent studies have suggested that the angiographically-derived point of maximum 
stenosis, or minimum lumen diameter (MLD), is not where the majority of unstable 
plaque is found [Kaple et al 2008; Tanaka et al 2006]. Furthermore, areas of necrotic-
rich plaque tend to exist more proximally than this point. These areas may be hidden 
within positively remodelled disease at the angiographic proximal reference segment, 
where relative normality of the vessel is conventionally assumed on angiography 
[Legutko et al 2013]. This has implications for angiographically-guided percutaneous 
coronary intervention (PCI). 
Most of our knowledge about the morphological characteristics of coronary lesions 
has previously been obtained from necropsy studies at the extreme end of the 
spectrum [Burke et al 2001]. The development of Intravascular Ultrasound (IVUS) 
with Virtual Histology TM (VH), using the spectral analysis of the radiofrequency 
ultrasound backscatter signals to identify specific components of the atherosclerotic 
plaque, has allowed us in-vivo, to delineate the relative contributions of different 
plaque types to lesions [Nasu et al 2006; Qian et al 2009; Hong et al 2008; Rodriguez 
Granillo et al  2006]. This evidence suggests that there may be multiple variations in 
the morphology of plaques, rather than the traditionally accepted view that a 
common pathological mechanism is at play [Maehara et al 2002]. The spectrum of 
coronary heart disease is heterogenous and many IVUS-VH studies suggest that 
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significant variations exist in the focal point of lipid, necrotic and calcified 
components of different plaques [Garcia-Garcia et al 2006; Hong et al 2008; Qian et al 
2009; Rodriguez-Granillo et al 2006; Surmely et al 2006; Nakamura et al 2006] 
Moreover, multiple more recent VH studies, including PROSPECT, VIVA and 
ATHEREMO (Stone et al 2011; Calvert et al 2011; Garcia-Garcia et al 2014) have 
suggested that plaques with a “higher-risk” for future events appear to have the 
following features:  Plaque burden >70%; Minimum Lumen Area (MLA) <4mm2; 
Presence of one or more VH-Thin Cap Fibroatheromas (VH-TCFA) 
7.2 Study Objectives 
We sought to determine the distance between the minimum lumen area (MLA) and 
the site of maximum necrotic core content (MAX NC) across the spectrum of 
coronary artery disease by measuring this on motorized (0.5mm/s) Intravascular 
Ultrasound (IVUS). The aim was to quantify the longitudinal relationship between 
these sites in:  
1. Acute coronary syndrome (ACS) culprit plaques (CP) 
2. Stable plaques (SP) 
3.  Non-culprit plaques - from adjacent plaque/vessels in ACS patients (NCP).  
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7.2.1 Hypotheses: 
1) The most significant necrotic core plaque does not occur at the angiographic 
MLD/IVUS derived MLA.   
2) The longitudinal distance between these sites varies related to clinical 
presentation. 
3) The prevalence of “higher risk” lesions types varies between clinical 
presentations. 
7.3 Methods 
These are as decribed in the general methods section and similar to previous 
chapters. In relation to this specific study, we measured the distance on IVUS 
pullbacks (at 0.5mm/sec) between the MLA and MAX NC site. Any MAX NC site 
within 1.5mm (3 frames at a heart rate of 60) of the MLA was rounded down to zero 
and taken to be part of the MLA lesion. This allowed us to decide whether the MAX 
NC frame occurs as part of the MLA lesion or not. Anything beyond 1.5mm 
proximally was taken as measured. Non-culprit plaques were taken distally to a 
culprit plaque (same vessel) in 16 patients and from a separate vessel in 4 patients. 
The proportional presence of the MAX NC plaque frame is displayed in length 
groups: 1. At MLA; 2. 1.5-5mm; 3. 5-10mm; 4. 10-15mm and 5. 15mm+. We have 
eliminated Nerotic Core or TCFA sites >1.5mm distal to the MLA, as these sites 
often tend to be part of another lesion developing (as part of diffuse disease) 
downstream. 
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7.4 Study specific statistics and power 
Simple descriptive statistics have been used to analyse the compositional differences 
and relative distances between MLA sites and MAX NC sites expressed in mm. On 
comparing sites a student’s t-test was used when the data was normally distributed, 
however if variances were unequal or a two sided F test was significant a Mann-
Whitney U test was performed to ensure statistical significant was met for median 
values. A P value of ˂0.05 was taken as indicating a statistically significant result.  
To ensure we had significant power to detect a difference we used data from our 
previous variability and magnitude of measurement error work [Murray et al 2012]. 
We know that the mean total plaque lengths for two different types of plaque are: 
CP 30.56±11.86 and SP 21.83±10.56.  Using these previous results, we were able to 
determine that 19 plaques in each group are required for 80% power to detect a 
difference with an alpha of 0.5 (95% CI). We have 70 CP, 35 SP and 20 NC plaques 
which should ensure adequate statistical power.     
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7.5 Results 
250 lesions sites within 125 vessels were examined from 105 patients (70 ACS and 
35 Stable). Patient characteristics across the spectrum of coronary disease studied are 
displayed in table 7.1.  The full details of plaque volume composition across the 
main groups are displayed within Table 7.2.  Further detailed analysis at each 
individual lesion site is shown in Table 7.3. Although complexity exists when 
comparing three groups at two separate sites, with regard to plaque components, 
general signals exist. At the MAX NC site there is greater vessel size, a greater lumen 
area and greater amounts of necrotic core compared to the MLA. Interestingly, even 
though angiographically the vessel lumen may appear reasonable, the plaque burden 
at the proximal MAX NC site always remains >40%. This occurs across all clinical 
presentations, indicating that there is still a definite lesion present here. With regard 
to outputs from a VH analysis, there appears to be differences in the absolute area of 
plaque types. However, when this is corrected for total plaque burden by the 
percentage composition of plaques (Table 7.2), the only difference that truly exists 
(as reported before in this thesis) is a greater presence of DC in stable plaques 
(p=0.014). 
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Table 7.1 – Patient Characteristics 
Characteristic 
 
ACS                     
N=70              
Culprit 
Plaque (CP)                     
ACS                              
N=20                                  
Non-Culprit 
Plaque (NCP) 
Stable Angina   
N=35                       
Stable Plaque   
(SP) 
Mean Age (±SD) 59.2 ± 11.0 57.3 ± 9.7 60.1 ± 7.8 
Male % 73% 60% 60% 
LAD/Diagonal 41% 55% 74% (p<0.05) 
Circumflex/OM 25% 35% 12% 
Right Coronary 34% (p=0.01) 10% 14% 
Mean Trop (±SD)        14.8 ± 27.2 n/a n/a 
Median Trop  (IQR) 1.4 (0.1-13.7) n/a n/a 
Hypertension 51% 44% 59% 
Diabetes 24% 21% 18% 
Current Smoker 54% 45% 57% 
Hypercholesterolaemia 60% 54% 52% 
Family History 70% 63% 65% 
CKD 3% 0% 1% 
Previous MI 16% (P<0.01) 10% 7% 
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Table 7.2 Simple plaque comparisons across the spectrum of coronary disease 
 
 
 
 
Mean Variable Culprit (CP)                                       
N=70 
Non-Culprit
(NCP)                          
N=20 
Stable  (SP)           
N=35 
p-value 
Fib Vol (mm3) 
Mean (±SEM) 
111.0 (±9.6) 59.0 (±9.9) 50.5 (±5.3) CP>Both       
(p<0.0001) 
FFatty Vol 
(mm3) Mean 
(±SEM) 
19.5 (±1.9) 11.1 (±2.4) 9.2 (±1.2) CP>Both     
(p<0.0001) 
NC Vol (mm3) 
Mean (±SEM) 
50.9 (±5.9) 25.5 (±7.9) 21.3 (±2.5) CP>Both   
(p<0.0001) 
DC Vol (mm3) 
Mean (±SEM) 
20.6 ( ±3.1) 9.8 (±2.7) 13.5 (±2.0) CP>NCP        
(p=0.014) 
Fib %             
Mean (±SEM) 
57.2 (±1.2) 59.2 (±1.9) 55.4 (±1.9) NS 
FF %               
Mean (±SEM) 
10.8 (±1.4) 10.5 (±0.8) 9.9 (±0.9) NS 
NC %            
Mean (±SEM) 
23.2 (±1.2) 21.5 (±1.9) 21.7 (±1.2) NS 
DC%             
Mean (±SEM) 
9.1 (±0.8) 8.7 (±1.1) 13.1 (±1.3) SP>Both      
(p=0.014) 
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Table 7.3 – IVUS measurements at MLA and MAX NC site per plaque type 
Mean 
Measurement 
Variable            
(±SEM) 
Culprit  ACS (CP)     
(N=140)                  
MLA        Max NC 
Stable Culprit (SP)         
(N=70)                        
 MLA     MAX NC     
Non-Culprit plaque      
(N=40)                                
 MLA       MAX NC 
Vessel area  14.8 
(±0.68) 
18.4 
(±0.81) 
4.0 
(±0.42) 
7.3 
(±0.72) 
12.0 
(±0.76) 
15.13 
(±1.1) 
Plaque area  11.8           
(±0.62) 
12.5 
(±0.64) 
12.7 
(±0.74) 
15.9 
(±1.0) 
8.4 
(±0.67) 
9.1 
(±0.70) 
Fibrous Area  5.3 
(±0.36) 
4.2 
(±0.24) 
8.7 
(±0.66) 
8.1 
(±0.94) 
3.3 
(±0.37) 
2.8 
(±0.37) 
Fibro-Fatty 
Area  
1.2 
(±0.12) 
0.45 
(±0.06) 
66.5 
(±2.5) 
49.0 
(±3.4) 
0.67 
(±0.10) 
0.36 
(±0.11) 
NC Area  2.1 
(±0.21) 
3.8 
(±0.31) 
3.5 
(±0.43) 
2.1 
(±0.45) 
1.4 
(±0.18) 
2.1 
(±0.22) 
DC Area  0.77 
(±0.08) 
1.1 
(±0.11) 
0.66 
(±0.10) 
0.26 
(±0.9) 
0.72 
(±0.11) 
0.99 
(±0.09) 
Fibrous %   58.2 
(±1.2) 
46.0 
(±1.3) 
1.3 
(±0.19) 
1.5 
(±0.21) 
53.7 
(±2.9) 
41.9 
(±2.2) 
Fibro-fatty %  13.0 
(±1.4) 
5.5 
(±0.70) 
0.67 
(±0.09) 
0.65 
(0.11) 
11.2 
(±1.3) 
5.0 
(±0.71) 
NC%  21.4 
(±1.3) 
37.5 
(±1.3) 
58.5 
(±2.9) 
43.3 
(±2.9) 
20.9 
(±1.9) 
34.2 
(±1.4) 
DC%  7.4 
(±0.98) 
11.1 
(±0.77) 
11.1 
(±1.6) 
3.7 
(±0.82) 
11.3 
(±1.6) 
17.3 
(±1.7) 
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With regard to the longitudinal distance between the MLA and MAX NC site, the 
distance as measured on IVUS motorized pullback is shown in Table 7.4, both mean 
and median values for each distance are shown.  
Table 7.4 – Differences in distance between MLA and MAX NC site for each 
plaque type 
 
 
Distance 
(mm) 
MLA-MAX 
NC 
Culprit ACS 
Plaque 
CP   (n=70) 
Non-culprit 
Plaque 
NCP  (n=20) 
Stable Plaque 
   SP  (n=35) 
0mm 
(@MLA) 
2/70 (2.9%) 5/20 (25%)  9/35 (25.7%) 
0-5mm 25/70 (35.7%) 6/20 (30%)  6/35 (17.1%) 
5-10mm 26/70 (37.1%) 9/20 (45%) 12/35 (34.3%) 
10mm + 17/70 (24.3%) 0/20 (0%)  8/35 (22.9%) 
Mean (±SD) 
Median (IQR) 
 
7.9mm (±4.9)  
6.2mm (4.3-18.1) 
 
4.1mm (±3.0) 
4.8mm (0-9.7) 
6.2mm (±5.4) 
5.4mm (0-9.4) 
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 The MAX NC site occurs at the MLA in around one quarter of stable and non-
culprit presentations but only 2.9% of culprit presentations. The spread of the MAX 
NC is displayed graphically in several formats to aid understanding. To determine 
the statistical differences between these multiple groups both a simple Mann-
Whitney U test was performed (between each group separately) and a Bonferroni 
multiple comparison test was performed. The main result (confirmed by both tests) 
was that culprit plaque MAX NC is statistically more proximal than that seen in non-
Culprit plaque (p=0.003). However on comparing stable plaque to non-culprit 
plaque and culprit plaque to stable plaque no difference was seen statistically 
between these groups (p=0.139 and 0.087 respectively). 
 
Figure 7.1 – A – Angiogram of Culprit lesion in LAD; B – MAX NC frame; C –
MLA frame.  
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Figure 7.2 is a spread plot detailing individual positions of the MAX NC at pre-
defined distances from the MLA and this is again displayed in a histogram for 
understanding (Figure 7.3). Finally, Figure 7.4 shows our findings per plaque type as 
it may be seen on a “angiographic-like” side-on representation of an IVUS-VH 
pullback. This final figure shows the mean differences between plaque types and that 
culprit plaques appear to have the greatest distance from MAX NC frame to the 
IVUS MLA. The IVUS MLA is used as a more accurate surrogate for the 
“angiographically perceived” minimum lumen diameter: CP mean 7.9mm (±4.9) Vs 
NCP mean 4.1mm (±3.0) Vs SP mean 6.2mm (±5.4). On statistical testing of these 
differences, individually it is clear that there is a statistical difference between CP and 
NCP. However, this does not exist between NCP and SP. When comparing CP and 
stable plaque there is a signal that the distance may be greater in CP, however this 
does not quite reach statistical significance with p=0.052.  
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Figure 7.2 – Spread plot of distance (mm) from MLA to 
MAX NC frame per plaque type. 
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Figure 7.3 – Histogram of distance (mm) and relative percentage of this from MLA 
to MAX NC frame per plaque type. 
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Table 7.5 – Prevalence of “high risk” plaques within the MAX NC 
frame.  
High Risk Plaque within 
MAX NC Lesion 
(Prospect/VIVA/Atheroemo 
Lesions)     
CP (N=70)                                 
Prevalence 
% 
NCP
(N=20)                                
Prevalence 
% 
SP (n=35)                                      
Prevalence 
% 
  
PB>70% / MLA<4 / VH-
TCFA 
 
35%           
 
20% 
 
19% 
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7.6 Discussion 
We have reported our original findings detailing the differential distances that exist 
between proximal unstable plaque components and the minimum lumen site as 
determined by IVUS-VH. This appears to occur with varying degrees across the 
spectrum of atherosclerosis.  Although this is not an entirely original concept, 
previous work has concentrated on one type of clinical presentation individually and 
the implications this has for stent implantation. In 2012, Legutko et al have 
separately addressed STEMI and NSTEMI culprit plaques finding that 50% of stents 
in STEMI do not cover the most proximal unstable part of the culprit plaque. This 
was repeated in NSTEMI and 35% of patients still had an uncovered proximal VH-
TCFA. Wykrzykowska et al in 2012 found that there is a gradient from proximal to 
distal in terms of the amount of necrotic core plaque that can be found and Sarno et 
al in 2011 suggested that 31% of stents do not cover proximal unstable plaque 
components. In the study which is most similar to ours, Kaple et al in 2008 found in 
81 stable patients that the MAX NC site was located at the MLA in 3.3% of patients. 
They found that 61% of lesions had a proximal MAX NC site by around 4mm. They 
concluded that the MLA is rarely the site of greatest instability and this is consistent 
with previous pathological analyses. Our investigation involved a greater amount of 
patients, vessels and plaque sites than in previous studies in this area and therefore 
further clarifies the intra-vascular relationship of plaque components to the MLA 
(perceived angiographic target). Our results suggest that when treating ACS culprit 
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lesions, the operator placing a stent should be mindful that consideration should be 
given to extending the stent proximally from the MLA by at least 10mm. This may 
be less conventional than the current teaching of allowing a 50:50 distribution of 
stent length coverage either side of the “perceived angiographic” MLA. It has been 
suggested by other authors (Legutko and Dudek et al 2012-2013) that there is a “culprit 
of the culprit” phenomenon that occurs in unstable plaques, where the necrotic rich 
rupture site occurs proximally and a thrombotic tail exists and extends into the more 
distal stable plaque that has a reduced luminal size. This cannot be proven well 
enough on IVUS due to the limited ability to truly define thrombus. 
Further intra-vascular imaging trials into this phenomenon should be conducted, 
particularly with Optical Coherence Tomography (OCT). This is able to visualize the 
point of plaque rupture, TCFA, presence of thrombus and length of plaque with 
much greater accuracy than IVUS [Prati et al 2013]. An operator blinded stenting 
trial, utilising new intra-vascular imaging modalities, should be performed. This 
might allow further clarification of this hypothesis and confirm with more precision, 
how far proximal a stent may need to be extended in ACS PCI (to ensure coverage 
of the rupture site). A future trial would also have to ensure adequate statistical 
power to compare clinical events during follow up, as it remains unknown whether 
this practice would alter hard end-points such as stent thrombosis and target vessel 
revascularisation. There may be a trade-off in risk with regard to increasing the 
length of stent implanted, although in the most recent trials utilizing IVUS for DES 
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implantation this does not appear true. This could not be done with any precision 
based on angiographic analysis alone, as it is impossible to know exactly where the 
most positively remodelled and necrotic-rich plaque is. It is hoped that recent results 
showing IVUS use improves outcomes, from studies such as ADAPT-DES 
[Witzenbichler et al 2014 ] and a recent meta-analysis of over 19,000 patients [Zhang et 
al 2012], may improve the current poor uptake of intra-vascular imaging during PCI. 
7.7 Limitations 
IVUS measurements and examinations have their own inter-catheter, inter-observer, 
inter-pullback and intra-observer variabilities. We previously addressed this with an 
in-depth measurement variability study [Murray et al 2012 ]. These results showed 
that our maximum measurement variability error for length measurement (calculated 
by the repeatability co-efficient from the within subjects standard deviation) was 
2.81mm for intra-observer and 4.82mm for inter-observers. These maximums must 
be contemplated particularly where different operators choose different starting 
frames for pullbacks or when pullback are done repeatedly on lesions. The 
motorized IVUS pullback at 0.5mm/s has now been eclipsed by rotational IVUS or 
OCT (in-sheath) pullback devices that suffer less from the effects of jumping and 
sticking in lesions. A strict policy was adhered to within this study regarding poor 
mechanical pullbacks. They were either repeated or dismissed as being unsuitable for 
analysis at an early stage.  
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Despite being able to state that there appears to be plaques types that differ 
compositionally along the length of a given plaque, we still have no evidence to 
support the concept that failing to treat the plaque completely, has a negative effect 
on hard end-points. We do know that somewhere between 12%-20% of ACS culprit 
lesion that are treated are subsequently responsible for further events [Prospect trial 
2009] Therefore, this part of our work can only hypothesise that misjudgements in 
plaque positioning and subsequent stent placement may contribute to the rate of  
these further events.  
7.8 Conclusions 
The angiographic “culprit” MLD point, when imaged as the MLA point on IVUS-
VH, often does not contain the most necrotic or “high-risk” plaque types as defined 
by virtual histology. These sites lie significantly more proximal in ACS patients 
compared with non-culprit plaques. This may have implications for stent 
implantation practices that are currently guided by angiography. 
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CHAPTER VIII 
STUDY V 
Observations of angiographically guided stent selection 
and placement during percutaneous coronary 
intervention for acute coronary syndromes: The 
potential influence of IVUS-VH assessment. 
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8.1 Introduction 
Angiographically-guided stent deployment is the conventional, albeit imperfect, 
approach in the setting of ‘real world’ percutaneous coronary intervention (PCI). 
Despite improvements in stent technology with third-generation drug eluting stents, 
stent  thrombosis and target lesion/vessel revascularisation rates (TLR/TVR) have 
not been abolished [Stefanini et al 2012; Takebayashi et al 2005] Whilst multiple factors 
contribute to the major limitations of PCI, it is well recognised that stent under-
sizing, under-deployment, inaccurate stent length selection and poor placement 
(“geographic miss”) can lead to long-term adverse events [Cutlip et al 1999; Zahn et all 
2005; Iakoyou et al 2005; Mauri et al 2008]. Previous work has also demonstrated that 
geographic miss is frequent (up to 50% of cases) and can result in both residual stent 
edge stenoses and an increase in target vessel revascularisation (TVR) [Suddath et al 
2010; Park et al 2013; Claessen et al 2011]. In the setting of acute coronary syndromes, 
post-mortem human studies of patients dying as a result of stent thrombosis have 
described the impact of incomplete stent coverage of necrotic core resulting in 
delayed endothelialisation, impaired thrombotic homeostasis and acquired late stent 
malapposition [Iakovou et al 2005; Palmerini et al 2012]. The ADAPT-DES study 
[Witzenbichler et al 2014] has suggested that the benefits of IVUS were especially 
evident in patients with acute coronary syndromes and complex lesions. Further 
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study is therefore required to understand the mechanistic aspects of how IVUS 
guidance could improve the placement and deployment of a stent. 
We therefore sought to determine the mechanistic nature of stent deployment 
during routine PCI for ACS in our large-volume, UK-based tertiary centre. Our aim 
was to analyse the Acute Coronary Syndrome (ACS) culprit plaque with IVUS-VH 
before and after angiographically-guided PCI. The PCI operator was initially blinded to 
the IVUS images relying solely on the angiographic interpretation. Our aim was to 
fully describe the mechanistic treatment of ACS lesions and to accurately measure 
stent architecture, deployment and residual plaque. The prevalence of any 
abnormalities, detailed stent measurements and compliance with known IVUS 
criteria for adequate stent deployment [Russo et al 2009; Chieffo et al 2013; de Jaegere et 
al 1998] are reported within this paper. 
8.2 Methods 
This has been described previously in our general methods section. Further study 
specific details, measurements and statistics are presented below. 
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8.2.1  Measurements and Statistics  
It is necessary to define what was measured at each stage to understand the 
subsequent results: 
IVUS analysis 1 (pre-intervention): Culprit Plaque Length; Reference vessel 
dimensions; lumen dimensions; plaque burden; IVUS-VH plaque composition. 
IVUS analysis 2 (post-intervention after operator satisfied): Residual plaque 
length; stent length; residual plaque burden; Minimum stent diameter; Maximum 
stent diameter; Minimum Stent Lumen Area (MLA); Maximum Stent Lumen Area; 
Frequency of observed longitudinal geographic miss; Frequency of residual plaque 
being of “high risk” nature (VH-TCFA); Frequency of stent edge dissection; 
Frequency of prolapsed material inside stent; Frequency of stent mallapposition. 
From these measurements, we were able to calculate some basic criteria known to 
define good stent deployment and these have been taken from the landmark MUSIC 
and AVID trials [Russo et al 2009; de Jaegere et al 1998]. 
 Min/Max Lumen Diameter (Should be >0.7) – marker of uniform stent 
deployment. 
 MLA/Av Ref Vessel Lumen Area (Should >0.8) – marker of stent result 
achieved relative to vessel. 
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 Minimum Stent Area Achieved (should always be >5.5mm2) – 
Correlates with better stent outcomes. 
From the above measurements, we have also calculated a new measurement to try 
and determine by how much the operator under-sizes and under-deploys stents in 
usual angiographic practice. We have called this the Calculated Under-Deployment 
Area (CUDA): This is calculated by the following: 
 Minimum stent area achievable (MSAach) = (π/4) × (Diameter of 
stent chosen)2 
 Calculated under deployment area = MSAach – IVUS measured 
minimum stent area (IVUS MSA). 
Figure 8.1: Worked example of CUDA for illustration purposes 
  
 
 
 
  (Stent Chosen 3.0mm diameter)     IVUS Measured MSA 
 MSAach (3.14/4) x (3)2 = (0.79) x (9) = 7.11mm2    5.7mm2 
CUDA = MSAach (7.11) – IVUS MSA (5.7) = 1.41mm2 
3mm 
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8.3 Results 
Table 8.1 – Basic characteristics for stent patients imaged 
Characteristic ACS                     
N=54             
Culprit Plaque 
(CP)                     
Mean Age (±SD) 55.2 ± 11.0 
Male % 70% 
LAD/Diagonal 61% 
Circumflex/OM 20% 
Right Coronary 19%  
Mean Trop (±SD)        14.8 ± 27.2 
Median Trop  (IQR) 1.4 (0.1-13.7) 
Hypertension 51% 
Diabetes 24% 
Current Smoker 54% 
Hypercholesterolaemia 60% 
Family History 70% 
CKD 3% 
Previous MI 16%  
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Table 8.2 – Final measured stent data after angiographic guidance 
 
Measured Stent Variable  Result  (Mean +/- SD) 
Post Stent Residual Plaque Burden (%) 49.20 (±7.45) 
Stent Min Lumen Diameter (mm) 2.51 (±0.54) 
Stent Max Lumen Diameter (mm) 4.18 (±0.65) 
Min/Max Lumen Diameter           
(Should be > 0.7) 
0.61 (±0.13)  
           21/58 (>0.7) = 36% 
Total Plaque Length (Pre-stent with 
PB>40%) (mm) 
31.63 (±12.11) 
Stented Length on IVUS (mm) 20.86 (±6.15) 
Residual Plaque Length (Post-stent 
PB>40%) 
14.60  (±11.56) 
Implanted Stent Diameter (mm) 3.33   (±0.49) 
Implanted Stent Length  (mm) 20.59 (±8.02) 
Minimum Stent Area Achieved (mm2)  
 (Should be >5.5)     
6.79 (±2.43)      
   38/58 (>5.5) =65.5% 
Min Stent Area Achievable (mm2)                 
(Theoretically for chosen stent size)      
8.87 (±2.68) 
Calculated Relative Under Deployment 
Area (mm2) 
2.08 (±1.87) 
Av Reference Vessel Lumen Area 
(mm2) 
10.58 (±2.51) 
MLA/Av Ref Vessel  Lumen Area              
(Should >0.8)  
0.66 (±0.24)   
   23/58 (>0.8) = 40% 
Maximum Stent Lumen Area (mm2) 7.83 (±2.38) 
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Table 8.3 – Relative frequencies of post PCI stent abnormalities 
 
Measured Variable +/- SD Result 
Frequency of Longitudinal Miss (Residual PB > 40%) 25/58 = 43% 
Frequency of “unstable” VH-TCFA  (in residual plaque) 9/58   = 15.5% 
Frequency of Stent Edge Dissection 5/58   =  8.6% 
Frequency of Incomplete Stent Apposition 13/58  = 22.4% 
Frequency of plaque prolapse/in-stent tissue 3/58  = 5.2% 
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Figure 8.2 – Histogram showing spread of IVUS MSA (mm2) in number 
of stents receiving post-dilatation. 
 
 
 
 
 
 
 
IVUS MSA (mm2) 
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Figure 8.3 – Histogram showing spread of IVUS MSA (mm2) in number 
of stents NOT receiving post-dilatation. 
 
 
 
 
 
 
 
 
IVUS MSA (mm2) 
[220] 
 
Figure 8.4 – Comparison of min, max and mean (+/- 95% CI) minimum 
stent area (mm2) for those stents post-dilated (PD+) and not post-
dilated (PD-) 
 
 
 
 
 
 
Box & whisker plot from STENT COMPARISONS PD.sdw
3 5 7 9 11 13
NO PD - Measured MSA Stent
PD+ Measured MSA Stent
min -[ mean ± 95% confidence interval ]- max
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Figure 8.5: Differences in maximum lumen stent area compared 
between post-dilated stents (PD+) and those with no post-dilatation.  
 
 
 
 
Box & whisker plot from STENT COMPARISONS PD.sdw
3 6 9 12 15
NO PD - Max Lumen Stent Area
PD + Max Lumen Stent Area
min -[ mean ± 95% confidence interval ]- max
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Figure 8.6 – Significant differences in MSA between PD and NO PD 
with highly significant statistical differences proving the benefits of 
luminal gain from post-dilatation. 
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Figure 8.7 – The statistical differences in the calculated under 
deployment area (mm2) between those stents with post-dilatation and 
those without. This shows that even with angiographic post-dilatation, 
under deployment still exists.  
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Figure 8.8 Comparisons of “ideal” stent sizes (based on predicted MSA 
in mm2) compared to those measured and achieved per stent with and 
without post-dilatation.  
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Figure 8.9 – Schematic of stent abnormalities seen with IVUS 
 
INAPPOSITION  UNDER-DEPLOYMENT EDGE TEAR 
8.4 Discussion 
We have shown that experienced operators in a tertiary cardiac centre, reliant on 
angiography alone, systematically undersize the vessel and then choose stents that 
are smaller than they should be. They then go on to deploy those stents 
inadequately, even despite some good improvements with routine post-dilatation. 
Although a “excellent” angiographic result is very often achieved and documented, 
this is not a reflection of what has happened intra-vascularly.  
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We have also shown that the prevalence of other stent and vessel abnormalities, at 
the end of a procedure, remains substantial.  
In the past, underpowered studies of IVUS-guided PCI in the bare metal stent era, 
failed to demonstrate superiority to angiography-guided PCI alone [Parise et al 2011]. 
Some of these trials were already influenced by the work from the Milan group, 
using larger post-dilatation balloons, inflated at high pressure. However, there is 
evidence now in the DES era to suggest that suboptimal deployment (defined by a 
cross-sectional minimal stent area <5.5mm2) is associated with higher TLR and ST 
rates [Roy et al 2008; Fuji et al 2005; Claessen et al 2010;  Zhang et al 2012] Recently, the 
ADAPT-DES (Assessment of Dual Anti-Platelet Therapy with Drug-Eluting Stents) 
trial [Witzenbichler et al 2014] reported that IVUS-Guidance improved clinical 
outcomes both acutely (<30 Days) and at 1 yr, with a 33% reduction in MI and a 
50% reduction in sub-acute and late stent thrombosis. These results are despite 40% 
more IVUS patients initially presenting with ST elevation myocardial infarction 
(STEMI). The benefits of IVUS were especially evident in patients with acute 
coronary syndromes and complex lesions. Overall, In ADAPT-DES, operators who 
used IVUS pre and post-procedure were found to achieve greater maximal lumen 
areas for proximal reference lumen area (8.9 vs. 7.6 mm2), in-stent lumen area (6.3 
vs. 5.8 mm2), and distal reference lumen areas (6.5 vs. 6.1mm2, P<0.001 for all 
measures). Greater maximum lumen area is identified as a key procedural factor to 
reduce risk for stent thrombosis with DES. Based solely on the IVUS evaluation, the 
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operator changed the PCI strategy in 74 % (2484/3349) of patients to choose (1) a 
larger stent or balloon (in 38% [943/2484] of cases); (2) higher inflation pressures (in 
23% [564/2484] of cases); (3) a longer stent (in 22% [546/2484] of cases); (4) 
additional post stent dilatation due to incomplete expansion (in 13% [329/2484] or 
incomplete stent apposition (in 7% [166/2484]); and/or (5) additional stent 
placement (in 8% [197/2484]). Moreover, a recent large meta-analysis by Zhang et al 
2012 has shown in 19,619 patients from both randomised and observational studies 
that a mortality benefit exists for IVUS guided stent implantation. This meta-analysis 
was then further enhanced [Zhang et al 2013] by the inclusion of three recent studies 
taking the total number of patients involved to 29,000. As described before, The 
ADAPT-DES [Witzenbichler et al 2014] trial was a prospective multicentre registry 
study that enrolled approximately 11,000 patients. The outcomes, after IVUS-guided 
percutaneous coronary intervention (PCI), were compared to the non-IVUS-guided 
PCI group in 8,575 patients. A significant reduction in the primary endpoint of 
definite/probable stent thrombosis was evident in patients who underwent PCI 
under IVUS guidance (vs. angiography guidance) at one-year follow-up (0.52% vs. 
1.04%, p=0.011).  
In the pre-specified long lesion subset of the RESET (Real Safety and Efficacy of a 
3-month Dual Antiplatelet Therapy Following Zotarolimus-eluting Stents 
Implantation) trial [Mintz et al 2012]; 543 patients were enrolled and randomised to 
either the IVUS or angiography-guided PCI group. IVUS-guided PCI was related to 
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a significantly lower risk of MACE at one-year follow-up compared to angiographic 
guidance (4.0% vs. 8.1%, p=0.048). In the AVIO trial, no statistical differences were 
observed in MACE (16.9% vs. 23.2%) or target lesion revascularisation (TLR, 9.2% 
vs. 11.9%) between the IVUS and angiography-guided groups [Chieffo et al 2013]. 
However, this final work is from a group known for their “IVUS-like” results using 
routine bigger post-dilatation balloons at high pressure. This may not be 
representative of that achieved elsewhere in the world. 
Based on the available data, the currently updated meta-analysis includes 14 studies 
involving 29,029 patients. This confirms the previous findings that IVUS guidance is 
associated with reductions in death (hazard ratio [HR]: 0.66, 95% confidence interval 
[CI]: 0.55-0.78, p<0.001), stent thrombosis (HR: 0.57, 95% CI: 0.44-0.73, p<0.001), 
myocardial infarction (MI) (HR: 0.74, 95% CI: 0.62-0.90, p=0.002) and MACE (HR: 
0.86, 95% CI: 0.77-0.95, p=0.003), but also shows the beneficial effect of IVUS 
guidance in reducing TLR (HR: 0.82, 95% CI: 0.68-0.97, p=0.02). This again 
suggests that IVUS guided DES implantation could saves lives. Following this 
important meta-analysis, there have now been three further large meta-analyses 
published [Jang et al 2014; Ahn et al 2014; Klersy et al 2013] each with >20,000 patients 
confirming the general trend that IVUS-guided DES implantation is associated with 
lower rates of adverse clinical events.  
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IVUS can also detect geographical miss, which has been shown to correlate with an 
increased frequency of TLR and acute MI [Costa et al 2008] In addition, late 
incomplete stent apposition is associated with a higher rate of MI and very late ST 
during long-term follow-up [Cook et al 2012]. This is mainly due to outward vessel 
remodelling, but acutely inapposed stents, due to stent under-sizing or inadequate 
deployment, are easily identified by IVUS.  
If we examine the data from SYNTAX, it is clear that despite how good we think we 
are at PCI, we have certainly not done well in the contemporary treatment of 
complex three vessel disease. The three year MACE rate was 28% with a repeat 
revascularisation rate of 19.7% and confirmed MI occurring in 7.1%.  Also, the 
IVUS sub-study of the HORIZONS-AMI study showed a post-procedure stent 
malapposition rate due to inappropriate stent size selection or underexpansion of 
35.2% [Choi SY et al 2011]. 
It may be that the lessons learnt from IVUS studies in the 1990s, regarding the use 
of larger post-dilatation balloons inflated to high pressure, should be re-enforced to 
Cardiologists of today’s DES era. A recent observational study from the UK [Rana et 
al 2014] has also shown that, despite high pressure post-dilatation of stents to 
standard criteria, only 54% reached the study end-point that defined good 
deployment. If these contemporary stent results are compared to the data from the 
2002 POST Registry [Uren et al 2002], there are striking similarities despite 15 years 
of progress within the field. In 53 stent thrombosis cases imaged as part of the 
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POST registry, there were approximately: 50% stents expanded less than 80% (from 
MUSIC criteria); 50% malapposition rate; 50% inflow-outflow disease; 
20% thombus; 20% edge tears and 15% plaque protrusion. Overall 94% had an 
IVUS abnormality, compared with a 30% rate of abnormality on angiography alone. 
Therefore, it is clear that despite these warnings, we have not moved on from our 
obsession with the angiogram as the guide to routine stent insertion.  
In light of our results, conducted in a high-volume tertiary cardiac centre, 
angiographically-guided stent procedures, in ACS patients, may be to the detriment 
of acute and long term stent results. Overall this could be one of the reason that PCI 
(in a stable setting) does not provide enormous advantages in mortality, yet IVUS-
guided comparison studies and meta-analyses (in the DES era) show mortality 
benefits. 
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8.5 Conclusions 
We have shown that utilizing angiography alone to guide the percutaneous treatment 
of ACS plaques can lead to several errors in both the initial selection of stent size 
and length. This data also suggests that symmetrical deployment and insufficient 
post-dilatation of the stents can lead to inadequate results. Experienced operators in 
a UK tertiary centre can systematically fail to achieve results that satisfy historical 
markers of proper stent implantation. This may have implications for subsequent 
target lesion or target vessel revascularization events, such as in-stent re-stenosis and 
stent thrombosis. A well-powered randomized trial of IVUS use is now required 
within the interventional cardiology community, to conclusively prove that these 
intuitive benfits will lead to a reduction in future MACE. 
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CHAPTER IX 
 
FINAL SUMMARY AND GENERAL CONCLUSIONS 
 
 
 
 
 
 
 
 
 
 
 
 
 
[233] 
 
This body of work started almost eight years ago now and since those intial 
descriptions, the field has changed and other work has been published. With regard 
to our findings, we have influenced the field with publications in three main areas so 
far: 
1. From the work carried out in Chapter IV, our initial magnitude of variability 
study has become a standard in the field.  The depth of study given to the 
possible measurement errors accrued by visibly interrogating IVUS-VH was a 
first. Moreover, the use of the repeatability co-efficient had never been done 
before in this line of investigation. Our initial hypothesis with regard to this 
was statistically proven at the level of agreement between an individual 
operator and between operators. However, the actual magnitude of 
measurement variability calculated for some virtual histology variables was 
found to be greater than initially thought in previously published studies in 
the literature. This has led to our study being cited related to the calculation 
of end-points and power for prospective studies in the field. This has 
included a recent Lancet publication by Joshi et al 2014. With regard to the 
overall thesis title, this measurement variability (even between experienced 
operators) certainly has an impact on the perceived clinical utility of this tool 
on percutaneous coronary intervention.  
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In addition, the time required to analyse and interpret the data in a frame by 
frame format is significant and is not conducive to immediate results within 
the catheter lab. This is a major limitation of the technique (yet to be 
overcome by recent versions). This limits any immediate role the technique 
has in changing the percutaneous strategy for the operators on the day, in 
“real-time”. 
2. Our second main piece of work began in an era where there was still some 
discussion about which plaque types were seen more often in ACS vs stable 
patients and our initial hypotheses were based upon this. However, after the 
publication of Prospect (Stone and Serruys et al 2011), which had results that 
were particularly disappointing, primarily due to the study design (see 
discussion in Chapter V). It became clear during our work that we had the 
opportunity to use the data differently to build a risk score, this had not been 
attempted before in intra-vascular imaging. I therefore began analyzing the 
IVUS and VH data based upon the statistical concept of logistic regression 
and ROC curve analysis. This allowed us to filter through the various plaque 
variables to concentrate on those that are the most important in determining 
the differences between recently active, acute coronary syndrome plaques and 
stable angina plaques. Interestingly, when the results were distilled, the purest 
predictors of a plaque that has recently been “active” were mainly grey-scale 
IVUS based and not Virtual Histology. One parameter Necrotic Core/Dense 
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Calcium ratio (NC/DC) did have an influence on the final risk score equation 
having an AUC of 0.78 with sensitivity, specificity and odds ratio for 
determining an active plaque of 80%, 70% and 1.56 respectively. By far the 
main determinants of a high risk plaque were the total plaque burden and 
remodelling index. These findings were not entirely novel, but the plaque risk 
score generated was and has now been cited several times in the field.  In 
addition, the methodology we used has now been recreated and applied by 
other investigators in the field of CT angiography of coronary plaques and in 
subdivided groups of patients such as diabetics.  
3. The work within chapter VI was influenced by the findings from the previous 
risk score. Of note, the risk score that was previously generated was based 
upon the total volume of plaque constituents seen within a given culprit 
plaque. We applied some of these findings to individual plaque areas at 
different sites within the plaques and also attempted to try and understand 
better the relationship that had been revealed statistically regarding the 
increase in dense calcium measurements within stable plaques. It is important 
to re-iterate here that we did not show any differences in the output from a 
standard VH analysis between stable and acute coronary syndrome plaques, 
other than in the relative amount of calcium. Calcium again can be clearly 
seen on a standard grey-scale analysis and therefore does not necessarily need 
the VH algorithm for this to influence a coronary intervention. This site-
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specific work was exploratory and experimental around the initial hypothesis 
that different sites within a single plaque have different compositional 
elements. The initial hypothesis was proven statistically in this work and has 
allowed us to understand that coronary plaque does changes significantly 
frame by frame along its length. Given that plaque anatomy can be somewhat 
heterogenous and unable to be judged (let alone seen in some cases) by basic 
angiography, these observations bring home the severe limitations of 
angiography alone. One major finding from this site-specific work was the 
fact that calcification in ACS related plaques tended to be spottier and 
nascent or less organized in a fixed arc. It is difficult to find a reliable measure 
of the spots of calcification seen and therefore we were reduced to using 
simple calculations (such as NC/DC) that would be able to summarise or 
assign a value to this phenomenon, to allow it to be compared. There are 
various flaws within this methodology as highlighted in the discussion and 
limitations section of that chapter. However, it was always felt that our work 
was very much observational, exploratory and hypothesis generating rather 
than definitive in the field. It is hoped that our theories from this work can be 
taken forward by more established research groups to fully understand the 
implications of spotty calcification and the possibility of stress interface 
mismatch points. The Edinburgh research group, led by Prof David Newby 
have recently found a Positron Emission Tomography (PET) tracer 18 F-
NaF that appears to be able to “light up” early or nascent micro-calcifications 
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within coronary plaques seen on CT scans. This shows early promise in 
correctly identifying those plaques that have been causative in generating 
clinically significant acute coronary syndromes. This appears to be the most 
exciting work in the field at the current time. 
Although the rest of the work in the final two chapters of this thesis remains 
currently unpublished or peer reviewed, ironically this work may highlight the 
most important role for intra-vascular imaging in PCI. This relates to 
determining the relationship between the angiographically-percieved 
narrowest point of the vessel (during an ACS) and the actual place where 
most of the plaque burden is placed. This appears to be almost universally 
within the proximal portion of the vessel before the stenosis. Positively 
remodelled plaque (in keeping with Glagov’s original theory) can be present 
at varying lengths from the narrowest angiographic point and the measured 
spread of the disease is occasionally greater than an operator might consider 
for stent length. Although now not a new concept in this field, our 
hypothesis was to look at the differences across the spectrum of coronary 
artery disease (stable/culprit and non-culprit) to see if there is a statistical 
difference and we have shown this with regard to the anatomy of a culprit 
plaque. The limitations of measuring on a single IVUS pullback have been 
discussed in our measurement error chapter and this may have cast some 
doubts on our ability to have millimetre accuracy. Despite this, the work 
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highlights an important warning for the operator to not become entirely 
focused on the angiographic “occulo-stenotic reflex” and to consider the 
possibility that the proximal vessel is heavily diseased and may require the 
stent to be extended proximally to cover this. Although this work does 
highlight some important points with regard to the anatomy of a plaque, it 
again does not appear to provide solid evidence of a role for the virtual 
histology element of the IVUS output and again points to the fact that simply 
using the IVUS in standard grey-scale mode tells you much more than you 
were aware of beyond standard luminography.  
Some recent work from studies such as PROSPECT, VIVA and 
ATHEROEMO has suggested that if you leave disease containing a Virtual 
Histology TCFA and an MLA <4mm2 then you are risking a future MACE 
event. Despite this, there are numerous difficulties with interpreting some of 
this data and a caution must be highlighted regarding the ability of simple 
operators to even identify a TCFA or to sub-classify plaques into the 
subgroups that have been purpoted by the key opinion leaders in this field 
(Garcia-Garcia, Calvert, Stone, Serruys et al). If anything the Virtual Histology 
part of the IVUS still remains too complicated for the average interventional 
cardiologist to completely understand and apply to their current practice. 
Whilst it has given us good surrogate insights into the true anatomy of 
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different plaque types, it is unlikely (in its current format) to affect routine 
decision making in the cath lab.  
From our observational perspective, we had a final group of hypotheses to be 
tested and this involved what a PCI operator does in everyday practice when 
placing stents in ACS lesions. The final chapter of this thesis takes the initial 
concept of intra-vascular plaque anatomy one step further to explore the 
mechanistic aspects of PCI in ACS. These blinded observations of intra-
vascualar stent placement and expansion generated many interesting results. 
With regard to our original hypotheses, we were able to quantify the 
prevalence of stent abnormalities generated and focus on those that have 
impacted upon outcomes and end-points in other trials. Specifically, we have 
shown that many stents are asymmetrically expanded, under-sized, under-
deployed or mallapposed. Furthermore, many stents do not cover all the 
plaque anatomy that is part of the active plaque. Some stents also create 
problems of their own with signs of dissection, plaque prolapse etc. These 
frequent abnormalities may have implications for future target vessel 
revascularization and therefore from a theoretical perspective could have 
been avoided, had IVUS revealed them at an early stage. Although this stent 
work was again observational and not powered to draw major conclusions, it 
has given us new insight into what can be expected from routine, 
angiographically-guided, PCI in ACS lesion. It has provided instructive data 
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that shows us all where we can improve our practice, particularly in the main 
areas linked to outcomes (stent MLA etc).  
It is sincerely hoped that these final chapters of work can be published in due 
course, in order to convey to other operators the clear pitfalls of angiographically-
guided PCI.  
In final summary, although the role of the virtual histology component of this 
technology does have some limitations, the use of IVUS remains strengthened by 
this work. Particularly in relation to having direct vision of vessel and plaque 
anatomy before undertaking the intervention and choosing the equipment sizes. It is 
also possible to ensure that no immediate complications have arisen from the PCI 
and the best final stent MLA has been achieved to prevent the spectre of stent 
thrombosis and re-stenosis. I can say that I have used IVUS and VH in my clinical 
practice outside this work and found it both intriguing and useful in most cases.  
Therefore, to answer the main question posed by this thesis as to whether virtual 
histology can have an impact on the percutaneous treatment of Acute Coronary 
Syndromes, I would have to conclude that IVUS alone, in basic grey-scale guise, can 
provide more than enough information over and above angiography to furnish the 
operator about the pattern, burden and anatomy of the disease being tackled. The 
use of the virtual histology aspect of this technology does have some niche 
advantages in very experienced hands and can provide excellent insight into plaque 
morphology that may influence lesion based treatments. Unfortunately, due to the 
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time involved in accurately processing the results, the average cardiologist’s lack of 
in-depth knowledge about VH and the limited impact that the findings from this are 
likely to have over and above grey-scale IVUS, I feel that it is not ready to be applied 
to all ACS PCI.  
Although throughout this work we have proved some interesting VH hypotheses 
and shown within the data that certain aspects of VH may help understand the 
plaque anatomy in more detail, this remains limited to the confines of plaque 
research. Overall, grey-scale IVUS can probably provide everything that is required 
to impact on improving the mechanistic aspects of PCI.  There are also more 
sensitive tools becoming used more frequently such as OCT which can provide 
more detail of the stent after deployment. On the horizon are newer techniques such 
as IVUS-HD, IVUS-NIRS, OCT-NIRS, OCT-NIRF and CT based plaque 
characterization that will probably take things further. This may even extend into the 
non-invasive realm, to allow plaque prevention to occur with medical therapy before 
the heart “attacks”.  
As a final point on the benefit of IVUS-guided PCI, several recent studies (including 
a large updated meta-analysis in over 20,000 patients) appear to suggest that there is 
a mortality advantage for the use of IVUS guided PCI (in the drug eluting stent era). 
This has not yet been tested in an adequately powered, prospective randomized 
controlled trial in an all-comers population. Without this important data IVUS may 
sadly continue to be confined to the “specialist adjunct techniques” available in PCI. 
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It is currently used in <10% of procedures in the UK and worldwide. This may 
unfortunately be to the detriment of some long term stent results and patient 
outcomes for the immediate future. 
 
Dr Scott W Murray 
March 2016 
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